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   1.INTRODUCTION 
 
1.1. Oral drug delivery system:     (Banker G.S. and Rhodes C.T., 2009; Chein Y.W., 2009; 
http://www.pharmainfo.net)    
Oral route has been the commonly adopted and most convenient route for the drug 
delivery. Oral route of administration has been received more attention in the 
pharmaceutical field, because of the more flexibility in the designing of dosage form than 
drug delivery design for other routes. The oral drug delivery depends on various factors 
such as type of delivery system, the disease being treated, the patient, the length of the 
therapy and the properties of the drug. Most of the oral controlled drug delivery systems 
(OCDDS) relay on diffusion, dissolution, or combination of both mechanisms, to release the 
drug in a controlled manner to the gastro intestinal tract (GIT). The physico-chemical 
properties include crystal nature, solubility, partition coefficient, intrinsic dissolution, etc. 
dosage form characteristics are controlled and optimized with respect to the physico-
chemical properties of the drug and relevant GI environmental factors. Other factors need to 
be considered are diseased state, the patient compliance & length of therapy. The goal of 
targeted oral drug delivery systems is to achieve better therapeutic success compared to 
conventional dosage form of the same drug. This could be achieved by improving the 
pharmacokinetic profile, patient convenience and compliance in therapy. 
Oral route of drug delivery has been known for decades as the most to a wide extent 
used route of administration among all the routes that have been travel through to learn 
about it the systemic delivery of drugs via various pharmaceutical manufactured products of 
various dosage forms.  
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Oral route of administration has been used as either conventional or novel drug 
delivery system. There are many merits are there for this, not the least of which would 
include willingness to accept by the patient and facility of administration. Types of 
sustained release system employed for oral route of administration include virtually every at 
the present time now the theoretical mechanism for such application. This is because the 
manufacturing of dosage form is more flexibility, since constraint, such as sterility problem 
and potential damage at the site of administration are minimized. Because of this, it is easy 
to development of different types of dosage forms by customary those developed for oral 
route of administration as initial examples. 
    Regarding orally administered drugs, targeting is not a primary concern, and it is 
usually done on purpose for active component to permeate to the blood circulation and 
permeation through the other body tissue (the obvious exception being medication intended 
for local gastrointestinal tissue treatment). For this justification, most system employed the 
sustained release variety. 
Concentration of drug level it will increasing the rate absorption region and also, 
increase circulating blood levels, which in turn to raise to greater concentration of active 
content at the site of action. 
1.2. Drawbacks of Conventional Dosage Forms:  (Brahmankar D.M. and Jaiswal S.B., 
2009; Shalin A. Modi, et al., 2011) 
1. Poor patient compliance, increased chances of missing the dose of a drug with 
short half-life for which frequent administration is necessary. 
2. The unavoidable fluctuations of drug concentration may lead to under medication 
or over medication. 
3. A typical peak-valley plasma concentration time profile is obtained which makes 
attainment of steady-state condition difficult. 
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4. The fluctuations in drug levels may lead to precipitation of adverse effects 
especially of a drug with small Therapeutic Index (TI) whenever over medication occur. 
1.3. Sustained release drug delivery system:  (Banker G.S. and Rhodes C.T., 2009; 
http://www.pharmainfo.net) 
Over past 30 year as the expanse and complication involved in marketing new drug 
entities have increased, with concomitant recognition of the therapeutic advantages of 
controlled drug delivery, greater attention has been focused on development of sustained or 
controlled release drug delivery systems. There are several reasons for the attractiveness of 
these dosage forms. It is generally recognized that for many disease states, a substantial 
number of therapeutically effective compounds already exist.  
The effectiveness of these drugs, however, is often limited by side effects or the 
necessity to administer the compound in a clinical setting, the goal in designing sustained or 
controlled delivery system is to reduce the frequency of dosing or to increase effectiveness 
of the drug by localization at the site of action, reducing the dose required, or providing 
uniform drug delivery. Sustained release constitutes any dosage form that provides 
medication over and extended time. Controlled release, however, denotes that the system is 
able to provide some actual therapeutic control, whether this is of a temporal nature, spatial 
nature or both.  
This correctly suggests that there are sustain release system that cannot be 
considered controlled release system. In general, the goal of a sustained release dosage form 
is to maintain therapeutic blood or tissue levels of drug for an extended period this is usually 
accomplished by attempting to obtain zero-order release from the dosage form; zero-order 
release constitutes drug release from the dosage form. Sustained release systems generally 
do not attain this type of release and provides drug is a slow first order fashion. In recent 
year sustained release dosage forms continue to draw attention in the search for improved 
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patient compliance and decreased incidence of adverse drug reactions. Sustained release 
technology is relatively cow field and as a consequence, research in the field has been 
extremely fertile and has produced many discoveries.  
Sustained release, sustained action, prolonged action controlled release, extended 
action, timed release, depot and repository dosage forms are terms used to identify drug 
delivery system that are designed to achieve or prolonged therapeutic effect by continuously 
releasing medication over an extended period of time after administration of a single dose. 
 
Figure 1.1: Plasma concentration versus time profile from conventional dosage and     
                   doses of sustained and controlled delivery formulation. 
 
Systems that are designed as prolonged release can also be considered as attempts at 
achieving sustained-release delivery. Repeat action tablets are an alternative method of 
sustained release in which multiple doses of drug are contained within a dosage form, and 
each dosage is related to a periodic interval. Delayed release systems, in contrast may not be 
sustaining, science often function of these dosage forms is to maintain the drug within the 
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dosage form for some time before release. Commonly the release rate of drug is not altered 
and does not result in sustained delivery once drug release has begun.  
Successful fabrication of sustained release products is usually difficult & and 
involves consideration of physicochemical properties of drug, pharmacokinetic behavior of 
drug, route of administration, disease state to be treated and, most importantly, placement of 
the drug in dosage form total will provide the desired temporal and spatial delivery pattern 
for the drug.  
The slow first order release obtained by a sustained release pre parathion is generally 
achieved by the release of the drug from a dosage form. In some cases in some cases, this 
achieved by making slow the release of drug from a dosage form. In some cases, this is 
accomplished by a continuous release process.  
1.3.1. Potential advantages of Sustained release drug delivery system:                       
(http://www.pharma info.net) 
1. Patient compliance due to reduction in the frequency of designing. 
2. Employ minimum drug. 
3. Minimize or eliminates local and systemic side effects. 
4. Obtain less potentiating or deduction in drug activity with chronic use. 
5. Minimize drug accumulation with chromic dosing. 
6. Improves efficacy in treatment. 
7. Cure or control confirm more promptly. 
8. Improve control of condition i.e. reduce fluctuation in drug level. 
9. Improve bioavailability of same drugs. 
10. Make use of special effects, e.g. sustained release aspect for morning relief of    
arthritis by dosing before bedtime. 
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1.3.2. Disadvantages of Sustained release drug delivery system:    (http: //www. 
pharmainfo.net)  
1.   They are costly. 
2.   Unpredictable and often poor in-vitro in-vivo correlations, dose dumping,        
      reduced potential for dosage adjustment and increased potential first pass    
      clearance. 
3.   Poor systemic availability in general. 
1. Effective drug release period is influenced and limited by GI residence time. 
1.3.3. Rationale of sustained release drug delivery system: (Ansel H.C., 2009; Vyas S.P 
and Khar R.K., 2002) 
 To optimizing the factor such as pharmacokinetic, pharmacodynamic and 
biopharmaceutical these are the rationale of sustained release dosage form, these properties 
of active ingredient in such a type its maximum reducing the adverse effect and controlling 
disease growth condition in short time period by loading less quantity of drug, when we are 
administered in the suitable route. Many drugs are longer action because half life and only 
need for once day dosing so these type of drug not for sustained or controlled release tablet 
to give therapeutic effect in blood and this nature of drug we can be manufacturing in 
immediate release tablet as like conventional tablet. However, some drugs are not long 
action and need multiple daily dosing to obtain the therapeutic results.  
 Multiple daily dosing is inconvenient for the patient, chance of missed doses, made 
up doses and non compliance with the regimen. When the conventional tablet which may 
causes variation of plasma level peaks and valley associated with the using of each dose. 
However, when a dose should not be administering such a manner because the obtaining 
result like peaks and valley give the less action of therapy. For example if a dosage form is 
administered short time interval, minimum toxic concentration of drug may be reached, with 
toxic side effect can occur. If doses are missed or forgetted, the administered drug goes to 
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sub therapeutic levels on those below the minimum effective concentration (MEC) may 
result, so there is no use to the patient. 
1.3.4. Designing sustained-release drug delivery system:       (Shalin A. Modi, et al., 
2011) 
 Most of the orally administered drugs, targeting is not a primary concern and it is 
usually intended for drugs to penetrate to the general circulation and perfuse to other body 
tissues. For this reason, most systems employed are of the sustained release variety. It is 
assumed that increasing concentration at the absorption site will increase circulating blood 
levels, which in turn, promotes greater concentration of drug at the site of action. If toxicity 
is not an issue, therapeutic levels can thus be extended. In essence, drug delivery by these 
systems usually depends on release from some type of dosage form, permeation through 
biological milieu and absorption through an epithelial membrane to the blood. There are a 
variety of both physicochemical and biological factors that come into play in the design of 
such system.  
 
1.3.5. Factors Affecting Sustained Release Dosage Forms:   (Chein Y.W., 2009; 
http://www.pharmainfo.net) 
1.3.5.1. Physicochemical properties of drug: 
a) Dose Size: 
If an oral product has a dose size greater that 0.5gm it is a poor candidate for 
sustained release system, Since addition of sustaining dose and  possibly the sustaining 
mechanism will, in most cases generates a substantial volume product that unacceptably 
large.  
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b) Aqueous Solubility:  
Most of drugs are weak acids or bases, since the unchanged form of a drug 
preferentially permeates across lipid membranes drugs aqueous solubility will generally be 
decreased by conversion to an unchanged form for drugs with low water solubility will be 
difficult to incorporate into sustained release mechanism. The lower limit on solubility for 
such product has been reported 0.1mg/ml. drugs with great water solubility are equally 
difficult to incorporate in to sustained release system. pH dependent solubility, particularly 
in the physiological pH range, would be another problem because of the variation in pH 
throughout the GI tract and hence variation in dissolution rate.  
c) Partition Coefficient: 
Partition coefficient is generally defined as the fraction of drug in an oil phase to that 
of an adjacent aqueous phase. Accordingly compounds with relatively high partition 
coefficient are predominantly lipid soluble and consequently have very law aqueous 
solubility. Compounds with very law partition coefficients will have difficulty in 
penetrating membranes resulting poor bioavailability.  
 
 
 
Figure 1.2: Typical relationship between drug activity and partition coefficient K. 
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d) Dissociation constant (pka):  
The relationship between dissociation constant of compound and absorptive 
environment. Presenting drug in an unchanged form is adventitious for drug permeation but 
solubility decrease as the drug is in unchanged form.  
e) Drug Stability:  
Orally administered drugs can be subject to both acid base hydrolysis and enzymatic 
degradation. Degradation will proceed at the reduced rate for drugs in the solid state, for 
drugs that are unstable in stomach, systems that prolong delivery ever the entire course of 
transit in GI tract are beneficial. Compounds that are unstable in the small intestine may 
demonstrate decreased bioavailability when administered form a sustaining dosage from. 
This is because more drug is delivered in small intestine and hence subject to degradation.  
f) Molecular size and diffusivity: 
The ability of drug to diffuse through membrane it’s so called diffusivity & diffusion 
coefficient is function of molecular size (or molecular weight). Generally, values of 
diffusion coefficient for intermediate molecular weight drugs, through flexible polymer 
range from 10-8 to 10-9 cm2 / sec. with values on the order of 10-8 being most common for 
drugs with molecular weight greater than 500, the diffusion coefficient  in many polymers 
frequently are so small that they are difficult to quantify i.e. less than 16-12 cm2/sec.  Thus 
high molecular weight drugs and / or polymeric drugs should be expected to display very 
slow release kinetics in sustained release device using diffusion through polymer 
membrane.  
g) Protein binding: 
It is well known that many drugs bind to plasma proteins with a concomitant 
influence on the duration of drug action. Since blood proteins are for the most part re-
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circulated and not eliminated, drug Protein binding can serve as a depot for drug producing 
a prolonged release profile, especially if a high degree of drug binding occurs.  
Extensive binding to plasma proteins will be evidenced by a long half life of 
elimination for drugs and such drugs generally most require a sustained release dosage 
form. However drugs that exhibit high degree of binding to plasma proteins also might bind 
to bio-polymers in GI tract which could have influence on sustained drug delivery.  The 
presence of hydrophobic moiety on drug molecule also increases the binding potential.  
1.3.5.2. Biological factors: 
a) Biological Half Life: 
The usual goal of an oral sustained release product is to maintain therapeutic blood 
levels over an extended period. To action this, drug must enter in the circulation of 
approximately the same rate of which it is eliminated. The elimination rate is quantitatively 
described by half-life (t1/2). Therapeutic compounds with short half lives are excellent 
candidates for sustained release preparations. Since this can reduce dosing frequency. In 
general drugs with half-lives shorter than 3hrs are poor candidates of sustained release 
dosage forms of dose size will increase as well as compounds with long half lives, more 
than 8 hrs are also not used in sustained release forms because their effect is already 
sustained.  
b) Absorption: 
The rate, extent and uniformity of absorption of a drug are important factors when 
considered its formulation into a sustained release system. As the rate limiting step in drug 
delivery from a sustained-release system is its release from a dosage form, rather than 
absorption. Rapid rate of absorption of drug, relative to its release is essential if the system 
is to be successful. It we assume that transit time of drug must in the absorptive areas of the 
GI tract is about 8-12 hrs. The maximum half life for absorption should be approximately 3-
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4 hrs. Otherwise device will pass out of potential absorption regions before drug release is 
complete.  
c) Distribution: 
The distribution of drugs into tissues can be important factor in the overall drug 
elimination kinetics. Since it not only lowers the concentration of circulating drug but it also 
can be rate limiting in its equilibrium with blood and extra vascular tissue, consequently 
apparent volume  of distribution assumes different values depending on time course of drug 
disposition. For design of sustained/ controlled release products, one must have information 
of disposition of drug.  
d) Metabolism: 
Drugs that are significantly metabolized before absorption, either in lumen or the 
tissue of the intestine, can show decreased bioavailability from slower-releasing dosage 
forms. Most intestinal wall enzymes systems are saturable. As drug is released at a slower 
rate to these regions less total drug is presented to the enzymatic. Process device a specific 
period, allowing more complete conversion of the drug to its metabolite. 
e) Side effects: 
 The incidence of side effect of a drug is depends on its therapeutic concentration 
level in blood. It can be remedy by the drug concentration level is controlled at which 
timing that drug exists in blood after administration. Toxic effect of a drug is expected 
above the maximum effective range level and fall in the therapeutic effect if a drug below 
the level of minimum effective range. So the above problem we can solve by making 
sustained release preparation. 
f) Margin of safety: 
 Therapeutic index of a drug is very important for either sustained or controlled 
release delivery system. Its value only desired the margin of safety. Therapeutic index value 
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it has been longer means excellent for preparation of sustained release tablet. Narrow 
therapeutic index of some drug precise to release the active content in therapeutic safe and 
effective range. Some drug like cardiac glycosides that therapeutic index value is very 
small, so it’s not used for sustained release delivery system.   
              Therapeutic index = TD50 ∕ ED50 
Where, TD50 - Median toxic dose 
             ED50 - Median effective dose. 
1.4. Oral controlled and sustained release systems:                    (Chein Y.W., 2009; 
http://www.pharmainfo.net; Shalin A. Modi, et al., 2011) 
The controlled release systems for oral use are mostly solids and based on 
dissolution, diffusion or a combination of both mechanisms in the control of release rate of 
drug. Depending upon the manner of drug release, these systems are classified as follows: 
1.4.1. Continuous release systems: 
These systems release the drug for a prolonged period of time along the entire length 
of gastrointestinal tract with normal transit of the dosage form. The various systems under 
this category are as follow, 
A. Dissolution controlled release systems 
B. Diffusion controlled release systems 
C. Dissolution and diffusion controlled release systems 
D. Ion exchange resin- drug complexes 
E. pH dependent formulation 
F. Osmotic pressure controlled systems 
A. Dissolution controlled release systems: 
These types of systems are easiest to design. The drug present in such system may 
be the one: 
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• With inherently slow dissolution rate e.g. Griseofulvin and Digoxin. 
• That produces slow dissolving forms, when it comes in contact with GI        
             fluids. 
• Having high aqueous solubility and dissolution rate. 
Drugs having high aqueous solubility and dissolution rate, shows challenge in controlling 
their dissolution rate. Dissolution-controlled release can be obtained by slowing the 
dissolution rate of a drug in the GI medium, incorporating the drug in an insoluble polymer 
and coating drug particles or granules with polymeric materials of varying thickness. The 
rate limiting step for dissolution of a drug is the diffusion across the aqueous boundary 
layer. The solubility of the drug provides the source of energy for drug release, which is 
countered by the stagnant-fluid diffusional boundary layer. The rate of dissolution (dm/dt) 
can be approximated by below equation.  
Dm/dt = ADS/h 
Where, S = Aqueous solubility of the drug. 
            A = Surface area of the dissolving particle or tablet. 
            D = Diffusivity of the drug and 
            h = Thickness of the boundary layer. 
a) Matrix (or monolithic) dissolution controlled systems: 
As the drug is homogeneously dispersed throughout the rate controlling medium, 
this system is also called as monolith system. It is very common and employs waxes such as 
bees wax, carnauba wax which control the drug release rate by controlling the rate of 
dissolution fluid penetration into the matrix by altering the porosity of tablet, decreasing its 
wettability or by itself getting dissolved at a slower rate. The drug release is often first order 
from such matrices. 
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b) Reservoir (Encapsulation) dissolution controlled systems: 
In this type, the drug particles are coated or encapsulated by one of the several 
microencapsulation techniques with slowly dissolving materials like cellulose and 
polyethylene glycol. The dissolution rate of coat depends upon the solubility and thickness 
of the coating. 
B. Diffusion controlled systems: 
The basic mechanism of drug release from these two systems is fundamentally 
different besides these simple systems, combination of reservoir and monolithic systems 
also exist in practice.Diffusion systems are characterized by release rate of drug is 
dependent on its diffusion through inert water insoluble membrane barrier.  
There are basically two types of diffusion devices.  
a) Reservoir devices    
b) Matrix devices  
a) Reservoir Devices: 
Reservoir Devices are those in which a core of drug is surrounded by polymeric 
membrane. The nature of membrane determines the rate of release of drug from system. The 
process of diffusion is generally described by a series of equations governed by Fick’s first 
law of diffusion.  
J = -D (DC/ DX)……. (1) 
Where, ‘J’ is the flux of drug across the membrane given in units of amount / area time.  
‘D’ is diffusion coefficient of drug in membrane in units of area / time. This is reflecting to 
drug molecule’s ability to diffuse through the solvent and is dependent on the factors as 
molecular size and charge.  
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‘dc/dt’ represents rate of change in concentration C relative to a distance X in 
the membrane.  
The law states that amount of drug passing across a unit area, is proportional to the 
concentration difference across that plane.  
 
Figure 1.3: Schematic representation of reservoir diffusion device Cm (o), and Cm                                                 
                  (d) represent concentration of drug inside surfaces of membrane and C (o)        
                  & C(d) represents concentration in adjacent  regions.  
If it is assumed that the drug on the both side of membrane is in equilibrium with its 
respective membrane surface which in equilibrium between the membrane surfaces and 
their bathing solutions as shown in Figure. Therefore the concentration just inside the 
membrane surface can be related to the concentration in the adjacent region by following 
expression.  
K = Cm (o) / C(d)      at  X = o                                  (2) 
K = Cm (d) / C(d)     at  X = d                                  (3) 
Where K = partition coefficient.  
If we consider K & D are constants then equation (1) becomes,  
J = D K C/d                                                            (4) 
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Where c is the concentration difference across the membrane and d is path length of 
diffusion. The simplest system to consider is that of slab, where drug release is from only 
one surface as shown Figure  in this case equation (4) becomes  
dMt/ dt  =    ADK C/ d                                           (5) 
 
Non permeable polymer shell 
Figure 1.4: Diagrammatic representation of slab configuration of reservoir diffusion       
                    system. 
Where Mt = Mass of drug released after time t, dMt/dt. Steady state drug release rate of 
time‘t’; A= surface area of device.  
In equation (7) if variables of right side of equation remain constant, then left side of 
equation represents release rate of system, a true controlled release system with a zero-order 
release rate.  
A constant effective area of diffusion, diffusional path length, concentration 
difference, and diffusion coefficient are required to obtain a release rate that is constant. 
Reservoir diffusional systems have several advantages over conventional dosage forms. 
They can after zero order release of drug, kinetics of which can be controlled by changing 
the characteristics of the polymer to meet the particular drug and therapy conditions.  
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Figure 1.5: Plot showing approach to steady state for reservoir device that has been      
                    stored for an extended period (the burst effect curve) and for device   
                    that has been freshly made (the time lag curve).  
Common methods used to develop reservoir type of devices include micro 
encapsulation of drug particles and press coating of tablets containing drug cores. In most 
cases particles coated by microencapsulation form a system where the drug is contained in 
the coating film as well as in the core of micro capsule. The drug release generally involves 
combination of dissolution and diffusion with dissolution being process that controls the 
release rate. If encapsulating material is selected properly will be the controlling process. 
Some materials such as membrane barrier coat alone or in combination, are hardened 
gelatin, methyl or methylcellulose, polyhydroxy methacrylate hydroxypropyl 
methylcellulose, polydroxy methacrylate, polyvinyl acetate & various waxes.  
Matrix devices:  
 A matrix device, as the name implies, consists of drug dispersed homogenously 
throughout a polymer.  
 
Figure 1.6: Matrix diffusion system before release (time=0) & after partial drug     
                    Release (time=t).  
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In this model drug in outside layer exposed to the bathing solution is dissolved first 
and diffused out of the matrix.  This process continues with the interface between  bathing 
solution and the solid drug moving controlled, the rate of dissolution of drug particles within 
the matrix must be faster that the diffusion rate of dissolved drug leaving matrix.  
Following assumptions are made in retrieving the mathematical models are:  
i. A pseudo steady state is maintained during drug release.  
ii. The diameter of drug particles is less than the average distance of drug Diffusion 
through the matrix.  
iii. The bathing solution provides sink conditions.  
iv. The diffusion coefficient of drug in the matrix remains constant.  
 The next equation that describes the rate of release drugs dispersed in an inert matrix 
system has been derived by Higuchi.  
 
Figure 1.7: Schematic representation of the physical model used for a planer slab    
                    matrix diffusion device.  
 The change in amount of drug released per unit area dM and change in the thickness 
of the zone of the matrix that has been depleted of the drug,  
dM/dh = Co dh – Cs /2                                               (6) 
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By Fick’s first law,  
dm = (Dm Cs/h) dt.                                                      (7) 
where, Dm is diffusion coefficient in matrix if equation (6)  & (7) are equated & solved for 
D that value of h sustituted back into the integrated form of equation (7) An equation for M 
is obtained.  
M= [Cs Dm (2Co – Cs) t] ½                                         (8) 
Similarly, a drug released from porous or granular matrix is described.  
                       M= [Ds Ca (є/τ) (2Co – є Ca) t] ½                                (9) 
Where,   e = Porosity of matrix  
               τ = tortuosity.  
              Ca = Solubility of drug in release medium  
              Ds = diffusion coefficient of drug in release medium.  
 In this system drug is leached from matrix through channels or pores.  
M = Kt½ 
                                       M = K √t                                (10) 
Where K is constantan so, that plot amount of drug released verses square root of time 
should be linear if the release of drug from the matrix is diffusion controlled.  The release 
rate of drug from such a device is not zero order, since if decreases with time but as 
previously mentioned, this may be clinically equivalent to constant drugs.  
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1.5. Matrix tablets: (Chein Y.W., 2009; Harnish Patel, et al., 2011) 
Introduction of matrix tablet as sustained release (SR) has given a new breakthrough 
for novel drug delivery system (NDDS) in the field of Pharmaceutical technology. It 
excludes complex production procedures such as coating and pelletization during 
manufacturing and drug release rate from the dosage form is controlled mainly by the type 
and proportion of polymer used in the preparations. Hydrophilic polymer matrix is widely 
used for formulating SR dosage form. Because of increased complication and expense 
involved in marketing of new drug entities, has focused greater attention on development of 
sustained release or controlled release drug delivery systems.  
Matrix systems are widely used for the purpose of sustained release. It is the release 
system which prolongs and controls the release of the drug that is dissolved or dispersed. In 
fact, a matrix is defined as a well-mixed composite of one or more drugs with gelling agent 
i.e. hydrophilic polymers. By the sustained release method therapeutically effective 
concentration can be achieved in the systemic circulation over an extended period of time, 
thus achieving better compliance of patients. Numerous SR oral dosage forms such as 
membrane controlled system, matrices with water soluble/insoluble polymers or waxes and 
osmotic systems have been developed, intense research has recently focused on the 
designation of SR systems for poorly water soluble drugs. 
1.5.1. Advantages of matrix tablets: 
• Easy to manufacture  
• Versatile, effective and low cost  
• Can be made to release high molecular weight compounds  
• The sustained release formulations may maintain therapeutic concentrations 
over prolonged periods.  
• The use of sustain release formulations avoids the high blood concentration.  
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• Sustain release formulations have the potential to improve the patient 
compliance.  
• Reduce the toxicity by slowing drug absorption.  
• Increase the stability by protecting the drug from hydrolysis or other 
derivative changes in gastrointestinal tract.  
• Minimize the local and systemic side effects.  
• Improvement in treatment efficacy.  
• Minimize drug accumulation with chronic dosing.  
• Usage of less total drug.  
• Improvement the bioavailability of some drugs.  
• Improvement of the ability to provide special effects.  
Ex: Morning relief of arthritis through bed time dosing. 
1.5.2. Disadvantages of matrix tablet: 
• The remaining matrix must be removed after the drug has been released.  
• High cost of preparation.  
• The release rates are affected by various factors such as, food and the rate 
transit through the gut.  
• The drug release rates vary with the square root of time. Release rate 
continuously diminishes due to an increase in diffusional resistance and/or a 
decrease in effective area at the diffusion front. However, a substantial 
sustained effect can be produced through the use of very slow release rates, 
which in many applications are indistinguishable from zero-order.  
 
1.5.3. Classification of matrix tablets:  
1.5.3.1. On the Basis of Retardant Material Used:  
Matrix tablets can be divided into 5 types.   
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1. Hydrophobic Matrices (Plastic matrices): 
The concept of using hydrophobic or inert materials as matrix materials was first 
introduced in 1959. In this method of obtaining sustained release from an oral dosage form, 
drug is mixed with an inert or hydrophobic polymer and then compressed in to a tablet.  
Sustained release is produced due to the fact that the dissolving drug has diffused 
through a network of channels that exist between compacted polymer particles. Examples of 
materials that have been used as inert or hydrophobic matrices include polyethylene, 
polyvinyl chloride, ethyl cellulose and acrylate polymers and their copolymers. The rate-
controlling step in these formulations is liquid penetration into the matrix. The possible 
mechanism of release of drug in such type of tablets is diffusion. Such types of matrix 
tablets become inert in the presence of water and gastrointestinal fluid.  
2. Lipid Matrices:  
 These matrices prepared by the lipid waxes and related materials. Drug release from 
such matrices occurs through both pore diffusion and erosion. Release characteristics are 
therefore more sensitive to digestive fluid composition than to totally insoluble polymer 
matrix. Carnauba wax in combination with stearyl alcohol or stearic acid has been utilized 
for retardant base for many sustained release formulation.  
3. Hydrophilic Matrices:  
Hydrophilic polymer matrix systems are widely used in oral controlled drug delivery 
because of their flexibility to obtain a desirable drug release profile, cost effectiveness, and 
broad regulatory acceptance. The formulation of the drugs in gelatinous capsules or more 
frequently, in tablets, using hydrophilic polymers with high gelling capacities as base 
excipients is of particular interest in the field of controlled release. Infect a matrix is defined 
as well mixed composite of one or more drugs with a gelling agent (hydrophilic polymer). 
These systems are called swellable controlled release systems.  
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The polymers used in the preparation of hydrophilic matrices are divided into three 
broad groups,  
A. Cellulose derivatives:  
 Methylcellulose 400 and 4000Cps, Hydroxy ethylcellulose; Hydroxypropyl 
methylcellulose (HPMC) 25, 100, 4000 and 15000Cps; and Sodium carboxy methyl 
cellulose.  
B. Non cellulose natural or semi synthetic polymers:  
Agar-Agar; Carob gum; Alginates; Molasses; Polysaccharides of mannose and 
galactose, Chitosan and Modified starches.  
Polymers of acrylic acid:  
Carbopol-934, the most used variety. 
4. Biodegradable Matrices:  
These consist of the polymers which comprised of monomers linked to one another 
through functional groups and have unstable linkage in the backbone. They are biologically 
degraded or eroded by enzymes generated by surrounding living cells or by non-enzymatic 
process in to oligomers and monomers that can be metabolized or excreted. Examples are 
natural polymers such as proteins and polysaccharides; modified natural polymers; synthetic 
polymers such as aliphatic poly (esters) and poly anhydrides. 
5. Mineral Matrices:  
These consist of polymers which are obtained from various species of seaweeds. 
Example is Alginic acid which is a hydrophilic carbohydrate obtained from species of 
brown seaweeds (Phaephyceae) by the use of dilute alkali.  
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1.5.3.2. On the Basis of Porosity of Matrix:  
Matrix system can also be classified according to their porosity and consequently, 
Macro porous; Micro porous and Non-porous systems can be identified:  
1. Macro porous Systems:  
In such systems the diffusion of drug occurs through pores of matrix, which are of 
size range 0.1 to 1 μm. This pore size is larger than diffusant molecule size.  
2. Micro porous System:  
Diffusion in this type of system occurs essentially through pores. For micro porous 
systems, pore size ranges between 50 – 200 A°, which is slightly larger than diffusant 
molecules size. 
 3. Non-porous System:  
Non-porous systems have no pores and the molecules diffuse through the network 
meshes. In this case, only the polymeric phase exists and no pore phase is present.  
1.5.4. Polymers used in matrix tablet:  
Hydrogels:  
Polyhydroxy ethyl methacrylate (PHEMA), Cross-linked polyvinyl alcohol (PVA), 
Cross-linked polyvinyl pyrrolidone (PVP), Polyethylene oxide (PEO), Poly acrylamide 
(PA). 
Soluble polymers:  
Polyethyleneglycol (PEG), polyvinyl alcohol (PVA), Polyvinyl pyrrolidone (PVP), 
Hydroxypropyl methyl cellulose (HPMC).  
Biodegradable polymers:  
Polylactic acid (PLA), Polyglycolic acid (PGA), Poly caprolactone (PCL), Poly 
anhydrides, Poly orthoesters.  
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Non-biodegradable polymers:  
Polyethylene vinyl acetate (PVA), Poly dimethyl siloxane (PDS), Polyether urethane 
(PEU), Polyvinyl chloride (PVC), Cellulose acetate (CA), Ethyl cellulose (EC).  
Mucoadhesive polymers:  
Poly carbophil, Sodium carboxy methylcellulose, Polyacrylic acid, Tragacanth, 
Methyl cellulose, Pectin.  
Natural gums: Xanthan gum, Guar gum, Karaya gum, Locust bean gum. 
1.5.5. Mechanism of drug release from matrix tablet: 
Drug in the outside layer exposed to the bathing solution is dissolved first and then 
diffuses out of the matrix. This process continues with the interface between the bathing 
solution and the solid drug moving toward the interior. It follows that for this system to be 
diffusion controlled, the rate of dissolution of drug particles within the matrix must be much 
faster than the diffusion rate of dissolved drug leaving the matrix. Derivation of the 
mathematical model to describe this system involves the following assumptions:  
a) A pseudo-steady state is maintained during drug release,  
b) The diameter of the drug particles is less than the average distance of drug diffusion 
through the matrix,  
c) The bathing solution provides sink conditions at all times.  
1.6. Methods used in tablet manufacturing:   (Lieberman H.A. and Lachman L., 1999; 
Ansel H.C., 2009; http://www.pharmainfo.net) 
Granulation:       
 Granulation may be defined as a size enlargement process which converts small 
particles into physically stronger & larger agglomerates. 
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The reason for granulation: 
  Become the pharmaceutical ingredient are free flowing 
  Increase the denseness of  ingredient 
  We can formulate uniform granular size that does not existing apart  
  Produce better  compression  characteristic  of  drug 
  Controlling  the  rate of  drug release from the dosage form 
  Reduce  dust in granulation technique 
  The  appearance  of  tablet can be achieved 
Methods: 
  1. Direct compression  
  2. Wet granulation 
  3. Dry granulation     
1.6.1. Direct compression: 
                In early days, most of the tablets require granulation of the powdered Active 
Pharmaceutical Ingredient (API) and Excipients. At the availability of new excipients or 
modified form of old excipients and the invention of new tablet machinery or modification 
of old tablet machinery provides an ease in manufacturing of tablets by simple procedure of 
direct compression. 
            Amongst the techniques used to prepare tablets, direct compression is the most 
advanced technology. It involves only blending and compression. Thus offering advantage 
particularly in terms of speedy production. Because it requires fewer unit operations, less 
machinery, reduced number of personnel and considerably less processing time along with 
increased product stability. 
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1.6.1.1. Definition:  
 The term “direct compression” is defined as the process by which tablets are 
compressed directly from powder mixture of API and suitable excipients. No pretreatment 
of the powder blend by wet or dry granulation procedure is required. 
1.6.1.2. The events that motivates the industry people to use direct compression 
technique:  
I. Commercial availability of the directly compressible excipients possessing  both good 
compressibility and good flowability. For example, Spray dried lactose, Anhydrous lactose,  
Starch-1500,  microcrystalline cellulose, Di-PacÒ, sorbitol. 
II. Major advances in tablet compression machinery: 
i)  Improved positive die feeding, 
ii) Precompression of powder blend. 
1.6.1.3 Merits: 
i) Direct compression is more efficient and economical process as compared to other 
processes, because it involves only dry blending and compaction of API and necessary 
excipients. 
ii) The most important advantage of direct compression is economical process. Reduced 
processing time, reduced labor costs, fewer manufacturing steps, and less number of 
equipments are required, less process validation, reduced consumption of power.  
iii) Elimination of heat and moisture, thus increasing not only the stability but also the 
suitability of the process for thermolabile and moisture sensitive API’s. 
iv) Particle size uniformity. 
v) Prime particle dissolution. 
 In case of directly compressed tablets after disintegration, each primary drug particle 
is liberated. While in the case of tablets prepared by compression of granules, small drug 
Sustained release matrix tablets of gliclazide                  Introduction 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  28 
 
particles with a larger surface area adhere together into larger agglomerates; thus decreasing 
the surface area available for dissolution. 
vi) The chances of batch-to-batch variation are negligible, because the unit operations 
required for manufacturing processes is fewer. 
vii) Chemical stability problems for API and excipient would be avoided. 
viii) Provides stability against the effect of aging which affects the dissolution rates. 
1.6.1.4. Merits over wet granulation process: 
 The variables faced in the processing of the granules can lead to significant tableting 
problems. Properties of granules formed can be affected by viscosity of granulating 
solution, the rate of addition of granulating solution, type of mixer used and duration of 
mixing, method and rate of dry and wet blending. The above variables can change the 
density and the particle size of the resulting granules and may have a major influence on fill 
weight and compaction qualities. Drying can lead to unblending as soluble API migrates to 
the surface of the drying granules. 
1.6.1.5. Demerits: 
Excipients Related:  
i) Problems in the uniform distribution of low dose drugs. 
ii) High dose drugs having high bulk volume, poor compressibility and poor 
flowability are not suitable for direct compression. 
iii) The choice of excipients for direct compression is extremely critical. Direct 
compression diluents and binders must possess both good compressibility and 
good flow ability. 
iv)  Many active ingredients are not compressible either in crystalline or amorphous 
forms. 
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v) Direct compression blends may lead to unblending because of difference in 
particle size or density of drug and excipients. Similarly the lack of moisture 
may give rise to static charges, which may lead to unblending. 
vi) Non-uniform distribution of colour, especially in tablets of deep colours. 
Process Related: 
i) Capping, lamination, splitting, or layering of tablets is sometimes related to air 
entrapment during direct compression. When air is trapped, the resulting tablets expand 
when the pressure of tablet is released, resulting in splits or layers in the tablet. 
ii) In some cases require greater sophistication in blending and compression equipments. 
iii) Direct compression equipments are expensive.  
1.6.1.6. Manufacturing steps for direct compression: 
 Direct compression involves comparatively few steps: 
•  Milling of drug and excipients. 
•  Mixing of drug and excipients. 
•  Tablet compression. 
 
Figure 1.8: Manufacturing Steps for Direct Compression. 
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1.6.1.7. Direct compression Excipients: 
 Direct compression excipients mainly include diluents, binders and disintegrants. 
Generally these are common materials that have been modified during the chemical 
manufacturing process, in such a way to improve compressibility and flowability of the 
material. 
 The physicochemical properties of the ingredients such as particle size, flowability 
and moisture are critical in direct compression tableting. The success of direct compression 
formulation is highly dependent on functional behavior of excipients. 
1.6.1.7.1. An ideal direct compression excipient should possess the following attributes:  
 i)  It should have good compressibility. 
ii) It should possess good hardness after compression, that is material should not possess 
any deformational properties; otherwise this may lead to capping and lamination of tablets. 
iii) It should have good flowability. 
iv) It should be physiologically inert. 
v) It should be compatible with wide range of API. 
vi) It should be stable to various environmental conditions (air, moisture, heat, etc.). 
vii) It should not show any physical or chemical change in its properties on aging. 
viii) It should have high dilution potential i.e. able to incorporate high amount of API. 
 ix) It should be colourless, odorless and tasteless. 
x) It should accept colourants uniformity. 
xi) It should possess suitable organoleptic properties according to formulation type, that is 
in case of chewable tablet diluent should have suitable taste and flavor. For example, 
mannitol produces cooling sensation in mouth and also sweet test. 
xii) It should not interfere with bioavailability and biological activity of active ingredients. 
xiii) It should be easily available and economical in cost. 
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Granulation method can be broadly classified into two types:  
• Wet granulation and  
• Dry granulation. 
1.6.2. Wet granulation: 
The most widely used process of agglomeration in pharmaceutical industry is wet 
granulation. Wet granulation process simply involves wet massing of the powder blend with 
a granulating liquid, wet sizing and drying. 
1.6.2.1. Important steps involved in the wet granulation: 
i)   Mixing of the drug(s) and excipients 
ii)  Preparation of binder solution 
iii) Mixing of binder solution with powder mixture to form wet mass. 
iv) Coarse screening of wet mass using a suitable sieve (6-12 # screens). 
v)  Drying of moist granules. 
vi) Screening of dry granules through a suitable sieve (14-20 # screen). 
vii)  Mixing of screened granules with disintegrant, glidant, and lubricant. 
1.6.2.2. Limitations of wet granulation: 
i)  The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labor, time, equipment, energy and space requirements. 
ii) Loss of material during various stages of processing  
iii) Stability may be major concern for moisture sensitive or thermo labile drugs  
iv) Multiple processing steps add complexity and make validation and control difficult. 
v) An inherent limitation of wet granulation is that any incompatibility between formulation 
components is aggravated. 
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1.6.3. Dry granulation: 
In dry granulation process the powder mixture is compressed without the use of heat 
and solvent. It is the least desirable of all methods of granulation. The two basic procedures 
are to form a compact of material by compression and then to mill the compact to obtain a 
granules. Two methods are used for dry granulation. The more widely used method is 
slugging, where the powder is pre-compressed and the resulting tablet or slug are milled to 
yield the granules.  
The other method is to pre-compress the powder with pressure rolls using a machine 
such as Chilosonator. 
1.6.3.1. Advantages: 
The main advantages of dry granulation or slugging are that it uses less equipments 
and space. It eliminates the need for binder solution, heavy mixing equipment and the costly 
and time consuming drying step required for wet granulation. Slugging can be used for 
advantages in the following situations: 
i) For moisture sensitive material 
ii) For heat sensitive material 
iii) For improved disintegration since powder particles are not bonded together by a binder 
1.6.3.2. Disadvantages: 
i) It requires a specialized heavy duty tablet press to form slug 
ii) It does not permit uniform colour distribution   
iii) Achieved with wet granulation where the dye can be incorporated into binder liquid. 
iv) The process tends to create more dust than wet granulation, increasing the potential 
contamination. 
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2. NEED AND OBJECTIVE 
 
• The basic goal of therapy is to achieve a steady state blood or tissue level that 
is  therapeutically effective  and  non-toxic  for  an  extended  period  of  time. 
Sustained release  drug delivery systems, with an aim of improved patient 
compliance, better therapeutic  efficacy, less side effects and reduced dosage 
regimen with less toxicity for treatment for many acute and chronic diseases. 
• Gliclazide is oral hypoglycaemic drug which lowers blood glucose level. It 
provokes  a   brisk  release  of  insulin  from  pancreas  and  shows  peculiar 
pharmacokinetic characteristics. It is extensively protein bound (87% to 94%) 
in circulation. It is first sulfonylurea for which it is possible to detail its action 
from the moment of oral administration through to it’s on long term glycemic 
control. Its plasma peak concentration occurs between 4 to 6 hours. Therefore, 
gastric and intestinal transient times have a significant effect on the rate and 
extent of oral absorption of the drug. 
• Matrix tablets are very useful in the field of healthcare for sustained release 
dosage regimen. 
• Keeping this in view, the present investigation has been aimed at designing 
suitable  sustained release matrix tablets using polymers as hydroxylpropyl 
methylcellulose and hydroxyl propyl cellulose. 
The major objectives of the investigation are as follows: 
 
 
1. To perform preformulation studies like flowing properties & bulking density 
for powders of drug and polymers. 
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2. To formulate matrix tablets of Gliclazide by wet granulation method by using 
different polymers like HPMC, HPC. 
3. To  evaluate  prepared  formulations  for  physical  parameters  like                      
weight variation, friability, and hardness etc.   
4.  To study in-vitro drug release performance of different tablets formulations. 
5.  To study the effect of different polymers on drug release. 
 
 
6. To ascertain the release mechanics and kinetics of drug release from 
compressed matrix tablets. 
7.  To perform stability studies as per ICH guidelines. 
 
BASIS FOR DRUG SELECTION AND DOSAGE SELECTION. 
 
• For  many drugs,  the  optimal  therapeutic  response  is  observed  only when 
adequate blood levels are achieved and maintained with minimum variations, 
(the matrix tablets will give more consistent blood levels). 
• Sulfonylurea with long half-life such as gliclazide has sustained stimulation on 
insulin  secretion  compared to repaglinide which has short half-life for only 
about 1 h. 
• Gliclazide with biological half-life is 10 to 12hr. It is oral hypoglycaemic drug 
which lowers blood glucose level and extensively protein bound in circulation. 
• It has been recommended for use on the basis of both its metabolic and non 
metabolic effects. 
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3. PLAN OF WORK 
                The present work was carried out to design and evaluate sustained-release 
tablets of Gliclazide, an anti diabetic drug. The sustained-release matrix tablets were 
prepared by direct compression method using HPMC K100M, ethyl cellulose, PVP 
K30, magnesium stearate and lactose keeping in view the objectives described above 
the following plan of work was adopted. 
THE SCHEME OF THE ENTIRE WORK IS LISTED AS FOLLOWS: 
 Literature review 
 Selection of drug and excipients 
 Procurement of drug and excipients 
 Physicochemical studies (organoleptic properties, melting point and solubility)  
  Standardization of the method and construction of calibration curve for the 
estimation of Gliclazide, quantification of drug. 
  Compatibility studies of drug and polymer by FTIR spectral and DSC studies 
 Formulation of Gliclazide sustained release matrix tablets by using polymers 
like HPMC K100M and ethyl cellulose and by direct compression method. 
   Evaluation of blend characteristics of  prepared granules (pre-compression 
parameters) 
i. Angle of repose 
ii. Determination of bulk density 
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iii. Determination of tapped density 
iv. Compressibility index 
v. Hausner ratio 
   Evaluation of physical parameters of Gliclazide sustained-release tablets (post-
compression parameters) 
                      i.    Thickness and diameter 
 ii.    Hardness 
iii. Friability 
iv. Weight variation 
v. Drug content  
 Evaluation of in vitro release characteristics of all formulations by using USP 
dissolution apparatus type I (Basket). 
 To study the mechanism of drug release by applying kinetic parameters. 
 To perform stability studies as per ICH guidelines.
  
 
 
 
 
 
 
 
 
 
 LITERATURE 
      REVIEW 
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4. LITERATURE REVIEW 
 
Ahmed A., et al. (2008) estimated the influence of EC with different viscosity grades 
on in vitro drug release from EC matrix tablets containing Indomethacin. Four viscosity 
grades were studied (7, 10, 50 and 100 cps). The drug release from the tablet is determined by 
dissolution testing as described in the USP. Based upon the pore characteristic studies which 
was determined by using helium pycnometry and mercury porosimetry the release rate 
constant has been found for different viscosity grades. From the result it is indicated the 
release rate is increased with an increase in viscosity grade. 
 
Amelia Avachat, et al. (2007) was developed and characterized an oral controlled 
release drug delivery system for concomitant administration of diclofenac sodium (DS) and 
chondroitin sulfate (CS). A hydrophilic matrix-based tablet using different concentrations of 
hydroxypropyl methylcellulose (HPMC) was developed using wet granulation technique to 
contain 100 mg of DS and 400 mg of CS. Formulations prepared were evaluated for the 
release of DS and CS over a period of 9 hours in pH 6.8 phosphate buffer using United States 
Pharmacopoeia (USP) type II dissolution apparatus. Along with usual physical properties, the 
dynamics of water uptake and erosion degree of tablets were also investigated. The in vitro 
drug release study revealed that HPMC K100 CR at a concentration of 40% of the dosage 
form weight was able to control the simultaneous release of both DS and CS for 9 hours. The 
release of DS matched with the marketed CR tablet of DS with similarity factor (f2) above 
50. 
Deepak S., et al. (2010) had developed sustained release formulation of quetiapine 
fumarate using HPMC and PVP K30. The study involves fixing the drug and polymer ratio 
for control the drug release up to the desired time. The effect of polymer concentration and 
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polymer blend concentration were also studied. Dissolution studies were performed in 0.1N 
HCl for 2 hrs and in phosphate buffer up to 12 hours. From the release it was observed that 
the polymer blend of HPMC/PVP K30 were successfully sustained the release of drug up to 
12 hrs.  
Gohel M.C., et al. (2007) was developed modified release of isoniazid using 
hydroxypropyl methylcellulose as a rate controlling agent. The low viscosity grade 
hydroxypropyl methylcellulose, medium viscosity grade hydroxypropyl methylcellulose and 
high viscosity grade Hydroxypropyl methylcellulose were used to prepare the matrix tablets. 
The tablets, prepared by direct compression, were subjected to physical characterization and 
in-vitro drug release studies. The release rate was strongly influenced by the type of polymer 
and concentration of polymer. 
Harris Shoaib M., et al. (2006) had formulated a once daily sustained release matrix 
tablet of ibuprofen using HPMC as release controlling factor and to evaluate drug release 
parameters as per various release kinetic models. The tablets were directly compressed using 
Avicel pH 101 and magnesium stearate. Different dissolution models were applied to drug 
release data in order to evaluate release mechanism. The drug release data fit well to the 
Higuchi expression. 
Indranil Kumar Yadav, et al. (2010) was developed the oral sustained release 
matrix tablets of aceclofenac using hydrophilic and hydrophobic polymers. Aceclofenac is a 
non steroidal anti-inflammatory agent used in symptomatic treatment of rheumatoid arthritis, 
osteoarthritis and ankylosing spondylitis and its biological half life is 4hrs. Controlled release 
formulations of aceclofenac (200 mg) were prepared by direct compression method. The 
tablets were subjected to physicochemical, in-vitro drug release and stability studies. The 
drug release from optimized formulations F1, F4 and F7 was extended for a period of 12 hrs. 
The optimized formulations were subjected to stability studies for three months at 45°C 
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temperature with RH 75±5%, and showed stability with respect to physicochemical 
parameters and release pattern. Results of the present study indicated the suitability of 
hydrophilic and hydrophobic polymers in the preparation of matrix based sustained release 
formulation of aceclofenac. 
Kalyani C., et al. (2009) had designed oral sustained matrix tablets of zidovudine 
using HPMC K4M, guar gum and ethyl cellulose as the retardant polymers. Factors like 
polymer proportion, polymer type and effect of filler type on the in vitro release of the drug. 
The formulations were prepared by wet granulation technique. The granules were evaluated 
and all formulations showed compliance with pharmacopoeial standards. Formulation F2 and 
F8 sustained the release for 12 hrs. Formulation F5 was found to be best which contains 15% 
HPMC using MCC as diluent release 10 hours only. 
Kumar pal T., et al. (2007) was designed an oral sustained release matrix tablet of 
metformin HCl and to optimize the drug release profile using response surface methodology. 
Tablets were prepared by non-aqueous wet granulation method using HPMC K15M as matrix 
forming polymer. 
Madhusmruti K., et al. (2010) was developed sustain release matrix formulation of 
Propanolol hydrochloride and investigate the effects of both hydrophilic and hydrophobic 
polymer on in-vitro drug release. Matrix tablets were prepared by direct compression method 
using different concentrations of Hydroxypropyl methyl cellulose (HPMC) and Ethyl 
Cellulose (EC). Prepared formulations were subjected to various studies like hardness, 
friability, thickness, % drug content, weight variation, dynamic of water uptake and erosion 
etc. Tablets were subjected to in-vitro drug release in 0.1N HCl (pH 1.2) for first 2 hours 
followed by phosphate buffer (pH 6.8) remaining time. 
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Patil U.K., et al. (2008) prepared and evaluated sustained release matrix tablet using 
natural polymers like pectin, guar gum and xanthan gum. Furosemide is used as the model 
drug and the formulations were compressed by a direct compression. The tablets were 
evaluated for physical characteristic and all the formulations were found to be in acceptable 
limits. Among the polymers guar gum was found to exhibit greater swelling index than pectin 
and xanthan gum.  
Paul J. Sheskey, et al. (1994) was studied the effect of roller compaction in the dry 
granulation of a controlled-release (CR) matrix formulation containing methylcellulose or 
hydroxypropyl methylcellulose (HPMC), niacinamide, and magnesium stearate. The authors 
investigated the use of roller compaction to enhance material flow in CR tablet formulations 
and evaluated the effect of roller compaction variables, such as roller pressure and product 
recycle, on tablet physical characteristics and drug-release profiles. 
Prabu Moses, et al. (2010) had formulated Ciprofloxacin controlled release matrix 
tablets using HPMC K100M, Guar gum, Carboxy methylcellulose, starch, polyvinyl 
pyrrolidone k30, magnesium stearate, isopropyl alcohol. Formulated tablets were taken to 
evaluation studies such as hardness, weight variation, friability, drug content and thickness. 
Raghuram Reddy K., et al. (2003) had formulated once daily sustained release 
matrix tablets of nicorandil, a novel potassium channel openers used in the treatment of 
cardiovascular disease. The tablets are prepared by wet granulation technique using ethanolic 
solutions of ethylcellulose (EC), Eudragit RL-100, Eudragit RS-100, and polyvinyl 
pyrrolidone as granulating agents with hydrophilic matrix materials such as HPMC, sodium 
carboxylic cellulose and sodium alginate.  The granules were studied for physiochemical 
characteristics and for evaluation parameters. Granules showed good flow property and tablet 
formulations are all within official limits. From the dissolution studies the formulation F1 
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could extend the release for 24 hrs and thus it exhibited the most successful formulation of 
the study. 
Raju Manda, et al. (2010) was developed a sustained release matrix tablet of 
aceclofenac using different natural polymers (Guar gum, Xanthan gum, Chitosan) in various 
proportions as release controlling factor by direct compression method. The in vitro 
dissolution study was carried out for 11 hours using United States Pharmacopoeia (USP) 1 
Basket-type dissolution apparatus in 0.1N hydrochloric acid for first 2 hours and phosphate 
buffer pH 7.4 for 9 hours. The in vitro release study shows that only F9 formulation was 
releases the drug in a sustained manner for 11 hours. This study explored the optimum 
concentration and effect of polymer(s) on acelofenac release pattern from the tablet matrix 
for 11 hour period. 
Saleh M. Saidan, et al. (2005) developed guar gum matrix tablets for oral controlled 
release of water-soluble Diltiazem hydrochloride prepared by using microcrystalline 
cellulose, starch, magnesium stearate and talc. In vitro drug release studies were performed 
using USP dissolution rate apparatus. 
Sandip B. Tiwari, et al. (2003) had formulated Tramadol hydrochloride using 
hydrophilic and hydrophobic matrix system for controlled release. The effect of concentration 
of hydrophilic and hydrophobic polymers on the release rate of Tramadol was studied. 
Hydrophilic matrix tablets prepared by wet granulation technique, while hydrophobic matrix 
tablets prepared by melt granulation technique. In vitro dissolution studies were performed. 
Saravanabhavan Shanmugam, et al. (2010) was developed sustained release matrix 
tablets of aceclofenac. The tablets were prepared with different ratios of hydroxypropyl 
methylcellulose K100M and ethylcellulose by wet granulation technique. The solubility study 
of the aceclofenac was conducted to select a suitable dissolution medium for in vitro drug 
release studies. In vitro dissolution study was carried out for all the formulation and the 
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results compared with marketed sustained release tablets. The drug release from matrix 
tablets was found to decrease with increase in polymer ratio of hydroxypropyl 
methylcellulose as well as ethylcellulose. Formulation F3 exhibited almost similar drug 
release profile in different dissolution media as that of marketed tablets.  
Seema Pushkar, et al. (2009) was developed the extended release tableted matrix 
devices for once daily dosing of diclofenac sodium, and their evaluation for performance and 
compliance with official pharmacopoeial and allied pharmaceutical requirements. The matrix 
tablets were prepared by drug incorporated polymer matrix, formulated using different 
combinations and ratios of hydroxypropyl methylcellulose (HPMC), sodium carboxy 
methylcellulose (Sodium CMC), and sodium alginate (NaAlg). Several preformulation trials 
were conducted to study the effect and optimization of various formulation and process 
parameters. The drug loaded polymeric matrices so prepared were compressed to tablets and 
studied for drug the release behaviour and comparative kinetic characterization along with six 
popular marketed brands of Diclofenac SR tablets. The formulated granules and tablets 
compressed complied with compendial and mechanistic requirements. The in vitro results 
shown a better release profile of formulated delivery system when compared to marketed 
brands extended up to 24 hours. The various formulations have shown an extended release up 
to 11 – 23 hours in different release environments. 
Sundaramoorthy K., et al. (2011) had formulated monolithic matrix tablets of 
metformin hydrochloride as extended release tablets by employing ethyl cellulose polymer 
and the extended release characterization of the formulated tablets was investigated. 
Extended release matrix tablets containing 500 mg metformin hydrochloride were developed 
by changing concentration of drug: polymer (EC) in the ratio of 5:1, 5:2, 5:3 and 5:4 by direct 
compression. Formulations were optimized based on the acceptable tablet properties in-vitro 
and in-vivo drug release. The result of in-vitro and in-vivo drug release studies indicated that 
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formulation (drug: polymer =5:3), was the most successful of the study and exhibited 
constant and extended release of metformin hydrochloride 99-100.5% release at the end of 10 
hours compared with reference standard. A decrease in release of the drug was observed on 
increasing polymer ratio at certain level. The t25%, t50% and t90% drug release values were 
calculated from selected formulation F3 on every specified period of stability studies and 
comparison of both room and accelerated condition by statistical t-test, there was no 
difference between storage temperature. The formulation F3 was showed similar in-vitro and 
in-vivo drug release when compared to market sustained release tablet (F5M). 
Literature review indicating work carried out on selected drug Gliclazide is given 
below:  
             Gopal Venkatesh Shavi1, , et al.  (2010)   Gliclazide is practically insoluble in water 
and its bioavailability is limited by dissolution rate. To enhance the dissolution rate and 
bioavailability the present study was aimed to formulate solid dispersions using different 
water soluble polymers such as polyethylene glycol 4000 (PEG 4000), polyethylene glycol 
6000 (PEG 6000) using fusion method and polyvinyl pyrrolidone K- 30 (PVP K 30) by 
solvent evaporation method. The interaction of gliclazide with the hydrophilic polymers was 
studied by Differential Scanning Calorimetry (DSC), Fourier Transformation-Infrared 
Spectroscopy (FTIR) and X-Ray diffraction analysis. Solid dispersions were characterized for 
physicochemical properties like drug content, surface morphology and dissolution studies. 
Various factors like type of polymer and ratio of the drug to polymer on the solubility and 
dissolution rate of the drug were also evaluated. Pharmacokinetic studies of optimized 
formulation were compared with pure drug and marketed formulation in wistar rats. The 
dissolution of the pure drug and solid dispersion prepared with PVP K 30 (1:1) showed 38.3 
+ 4.5 % and 95 + 5.2 % release respectively within 30 min. Peak plasma concentration of 
pure drug, solid dispersion (PVP K 30) and marketed formulation was found to be 8.76 + 2.5, 
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16.04 + 5.5 and 9.24 + 3.6 μg/ml respectively, from these results it was observed that there is 
two fold increase in peak plasma concentration compared to pure drug. Solid dispersion is an 
effective technique in increasing solubility, dissolution rate and bioavailability of the poorly 
soluble drugs.  
            P.N. Dhabale, , et al. (2010) Two simple, accurate, precise, reproducible and 
economical procedures for simultaneous estimation of Gliclazide(GLZ) and Metformine 
hydrochloride (MET) in tablet dosage form have been developed. First method based on 
solving of simultaneous equation using 228 nm (λmax of GLZ) and 234 nm (λmax of MET) 
as two analytical wavelengths for both drugs in mixture of Water and Methanol (60:40) 
solvent. Second method based on an equation of area calculation of curve at two wavelength 
resion (233 to 223nm and 239 to 229 nm).Linearity was observed in the concentration range 
of 2-24 μg/ml for GLZ and 2-14 μg/ml for MET. The result of analysis have been validated 
satistically and by recovery study.   
            Panchal V.N, etal. (2011)  The objective of the present study was to develop “once 
daily” sustained release tablets of gliclazide by wet granulation using hydroxy propyl methyl 
cellulose,  hydroxy propyl cellulose and their combination as polymers. The drug excipient 
mixtures were subjected to preformulation studies while the tablets were subjected to 
physicochemical studies, in vitro drug release, stability studies and validation studies. The 
physicochemical properties of tablets were found within the limits. Formulation F6 & F9 
containing HPMC K4M and HPMC K4M & HPC 75-100 cps combination respectively were 
found to release the drug in sustained manner upto 12 hour and were stable under accelerated 
conditions of temperature for 6 months since there were no significant changes in drug 
content and physical parameters.  
RajeshKaza, etal. (2012)  The enhancement of oral bioavailability of poorly water-
soluble drugs remains one of the most challenging aspects of drug development. Gliclazide 
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(GLZ) BCS class II drug, is an oral antihyperglycemic agent used for the treatment of non-
insulin-dependent diabetes mellitus However, low aqueous solubility and poor dissolution of 
this molecule, delays its rate of absorption and finally the onset of action. Solid dispersion 
has been successfully utilized as dissolution enhancement technique using natural polymers 
for wide variety of poorly water-soluble drugs. The present study aims at enhancement of 
dissolution profile of Gliclazide using Xanthan gum, Guar gum and Hupu gum as carriers by 
solid dispersion technique. Solid dispersion containing GLZ was further investigated by 
Fourier transform infrared spectroscopy (FTIR). FTIR patterns suggest that there is no 
interaction between drug and excipients. From the study it concluded that the in vitro 
dissolution of Gliclazide can be enhanced by solid dispersion technique. Amongst the solid 
dispersions prepared. F6 formulation prepared by co-grinding method using Guar gum as 
carrier in 1:3 ratio shown the better release of Gliclazide (96.79 %) with in 60 min.             
          S. Areefulla Hussainya, et al.  (2012) The objective of the present study is to evaluate 
HPMC K100M, HPMC K4M and carbopol 934P as matrix formers in this design of floating 
tablets of gliclazide, a poorly water soluble drug. Floating tablets of gliclazide (60 mg) were 
formulated employing (i) HPMC K100M (ii) HPMC K4M and (iii) Carbopol 934P as matrix 
formers at 30% and 50% strength, sodium bicarbonate at 7.5%, 10% & 12.5% strength as gas 
generating agent and bees wax (10%) as floating enhancer and the tablets were evaluated for 
floating and drug releases characteristics. Gliclazide floating tablets formulated employing 
HPMC K100M and HPMC K4M as matrix formers at 50% strength and containing sodium 
bicarbonate (12.5%) as gas generating agent exhibited floating over 31 to 44 h with a floating 
lag time of less than 1 min. These floating tablets also gave slow and controlled release of 
gliclazide over 24 h and were found suitable for once a day administration (24 h). HPMC 
K100M and HPMC K4M were better suitable as matrix formers than Carbopol 934P for 
floating tablets of gliclazide, a poorly water soluble drug. 
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            Sandra Grbic,et.al, (2011) The aim of this study was to develop a drug-specific 
absorption model for gliclazide (GLK) using mechanistic gastrointestinal simulation 
technology (GIST) implemented in GastroPlusTM software package. A range of 
experimentally determined, in silico predicted or literature data were used as input 
parameters. Experimentally determined pH-solubility profile was used for all simulations. 
The human jejunum effective permeability (Peff) value was estimated on the basis of in vitro 
measured Caco-2 permeability (literature data). The required PK inputs were taken from the 
literature. The results of the simulations were compared with actual clinical data and revealed 
that the GIST-model gave accurate prediction of gliclazide oral absorption. The generated 
absorption model provided the target in vivo dissolution profile for in vitro–in vivo 
correlation and identification of biorelevant dissolution specification for GLK immediate-
release (IR) tablets. A set of virtual in vitro data was used for correlation purposes. The 
obtained results suggest that dissolution specification of more than 85% GLK dissolved in 60 
min may be considered as “biorelevant” dissolution acceptance criteria for GLK IR tablets. 
             Samina A. Jamadar , et.al. (2011) The article describes a simple, sensitive, rapid, 
accurate and precise spectrophotometric method for the estimation of gliclazide in bulk and 
pharmaceutical dosage forms. The wavelength maxima for gliclazide was found to be 229.5 
nm with molar absorptivity of 1.4962×104l/mol/cm. Beer’s law was obeyed in the 
concentration range of 7-27 μg/ml. The limit of detection (LOD) and limit of quantification 
(LOQ) were found to be 0.31 μg/ml and 0.92 μg/ml, respectively. The percentage recovery of 
the drug for the proposed method ranged from 98.68-100.12% indicating no interference of 
the tablet excipients. The results demonstrate that proposed method is accurate, precise, and 
reproducible while being simple and rapid too for the determination of gliclazide in tablet 
dosage form. 
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5. DRUG AND EXCIPIENTS PROFILE 
 
5.1. Drug profile: 
 
GLICLAZIDE 
 
 
 
 
Gliclazide, 1-(3-azabicyclo (3.3.0) oct-3-yl)-3-ptolylsulphonylurea is an oral hypoglycemic 
agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It 
contains not less than 99.0 % and not more than the equivalent of 101.0% of 1-
(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(4-methylphenyl)sulphonyl]urea,  calculated 
with reference to the dried substance. 
 
Characteristics: A white or almost white powder. 
 
Melting point: 180ºC-182ºC 
                     
Solubility: 
 
Practically insoluble in water, freely soluble in methylene chloride, 
sparingly soluble in acetone, slightly soluble in alcohol. 
Pharmacological effects: 
Gliclazide is oral hypoglycaemic drug which lowers blood glucose level. It 
provokes a brisk release of insulin from pancreas and shows peculiar pharmacokinetic 
characteristics. 
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Pharmacokinetics: 
 
It  is  extensively  protein  bound  (87%  to  94%)  in  circulation.  It  is  first 
sulfonylurea  for which it is possible to detail its action from the moment of oral 
administration  through  to  it’s  on  long  term  glycemic  control.  Its  plasma  peak 
concentration occurs between 4 to 6 hours. Therefore, gastric and intestinal transient 
times have a significant effect on the rate and extent of oral absorption of the drug. 
Therapeutic uses: 
This medication  is  used  in  conjunction with  diet  and  exercise regimens  to 
control high blood sugar in non-insulin dependent diabetic patients. Controlling high 
blood sugar helps prevent heart disease, strokes, kidney disease, circulation problems, and 
blindness. 
Preparation: 
 
Gliclazide tablets each containing 30 mg, 40 mg and 60 mg of Gliclazide are 
official in  USP and  BP. Tablets containing 30  mg and 40 mg of Gliclazide are 
available commercially in the market. 
 
Mechanism of action: 
Sulfonylureas provoke a brisk release of insulin from pancreas. They act on the 
so called sulfonylurea receptors (SUR1) on the pancreatic β cell membrane-cause 
depolarization by reducing conductance of ATP sensitive K+   channels. This enhances Ca 
2+ influx degranulation. The rate of insulin secretion at any glucose concentration is 
increased. In type 2 DM the kinetics of insulin release in response to glucose or meals is 
delayed and subdued. 
 
Dose:  40 mg to 320 mg twice a day. 
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Side effects: 
 
Hypoglycaemia: - It is the commonest problem, may occasionally be severe and rarely 
fatal. It is  more commonly in elderly, liver and kidney disease patients and when 
potentiating drugs are added. 
Hypersensitivity:  -  Rashes,  photosensitivity,  purpurea,  transient  lukopenia,  rarely 
agranulocytosis. 
Nonspecific side  effects: - Nausea, vomiting, flatulence, diarrhea or constipation, 
headache, paresthesias and weight gain 
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5.2. Excipients profile: 
 
HYDROXY PROPYL METHYL CELLULOSE 
Synonyms:  Benecel, HPMC, Methocel, Hydroxy propyl methyl cellulose 
Molecular weight: 10,000-15,000 
Structure: 
                       
Description : slightly off-white to beige powder in appearance and may be 
formed into granules. 
Colour  : white to yellowish white 
Odour   : odorless or nearly odorless 
Taste   : bland taste 
Texture  : powder 
Acidity / Alkalinity : pH 5.5-8.0 for a 1%w/w aqueous solution. 
Viscosity for 2 %( w/v) aqueous solution:   4000mpas (Viscosity measured at 200C) 
 Solubility: 
  Soluble in cold water, forming a viscous colloidal solution, practically insoluble in 
mixtures of ethanol and dichloromethane, mixtures of alcohol and water 
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Functional category:   
Coating agent, film former, and rate controlling polymer for sustained release, 
stabilizing agent, suspending agent and viscosity builder. 
Applications in pharmaceutical technology: 
High viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10-80%w/w in tablets and capsules. 
Stability and Storage:  
Stable between pH 3-11, should be stored in a well-closed container in a cool and 
dry place. 
Incompatibilities:  
Incompatible with some oxidizing agents such as hydrogen peroxide, potassium 
permanganate. 
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ETHYL CELLULOSE 
Nonproprietary Names: 
BP: Ethyl cellulose 
PhEur: Ethyl cellulose 
USP-NF: Ethyl cellulose 
Synonyms: Aquacoat ECD; Aqualon; Ashacel; E462; Ethocel; ethylcellulosum;Surelease. 
Chemical Name: Cellulose ethyl ether  
CAS Registry Number: [9004-57-3] 
Empirical Formula and Molecular Weight: Ethyl cellulose is partially ethoxylated. Ethyl 
cellulose with complete ethoxyl substitution (DS = 3) is C12H23O6 (C12H22O5) nC12H23O5 
where n can vary to provide a Wide variety of molecular weights. Ethyl cellulose, an ethyl 
ether of cellulose, is a long-chain polymer of b- anhydroglucose units joined together by 
acetal linkages. 
Structural Formula: 
 
 
Functional Category: 
Coating agent, flavouring agent, tablet binder, tablet filler, viscosity increasing agent. 
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Description: 
Ethyl cellulose is a tasteless, free-flowing, and white to light tan-colored powder. 
Color                    :      white to light tan-colored powder 
Odour                 :      odorless. 
Taste     :      tasteless 
Texture    :      powder  
Solubility:  
Ethyl cellulose is practically insoluble in glycerin, propylene glycol, and water. Ethyl 
cellulose that contains less than 46.5% of ethoxyl groups is freely soluble in chloroform, 
methyl acetate, and tetrahydrofuran, and in mixtures of aromatic hydrocarbons with ethanol 
(95%). Ethyl cellulose that contains not less than 46.5% of ethoxyl groups is freely soluble 
in chloroform, ethanol (95%), ethyl acetate, methanol, and toluene. 
Stability and Storage Conditions: 
Ethyl cellulose is a stable, slightly hygroscopic material. It is chemically resistant to 
alkalis, both dilute and concentrated, and to salt solutions, although it is more sensitive to 
acidic materials than are cellulose esters. Ethyl cellulose is subject to oxidative degradation 
in the presence of sunlight or UV light at elevated temperatures. This may be prevented by 
the use of antioxidant and chemical additives that absorb light in the 230–340nm range. 
Ethyl cellulose should be stored at a temperature not exceeding 328C (908F) in a dry area 
away from all sources of heat. It should not be stored next to peroxides or other oxidizing 
agents. 
Incompatibilities: 
Incompatible with paraffin wax and microcrystalline wax. 
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Applications in Pharmaceutical Formulation or Technology 
 Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
 The main use of ethyl cellulose in oral formulations is as a hydrophobic coating 
agent for tablets and granules. Ethyl cellulose coatings are used to modify the release 
of a drug, to mask an unpleasant taste, or to improve the stability of a formulation. 
For example where granules are coated with ethyl cellulose to inhibit oxidation. 
  Modified-release tablet formulations may also be Produced using ethyl cellulose as 
a matrix former. Ethyl cellulose, dissolved in an organic solvent or solvent mixture, 
can be used on its own to produce water-insoluble films. 
 Drug release through ethyl cellulose-coated dosage forms can be controlled by 
diffusion through the film coating. This can be a slow process unless a large surface 
area (e.g. pellets or granules compared with tablets) is utilized. In those instances, 
aqueous ethyl cellulose dispersions are generally used to coat granules or pellets. 
 Ethyl cellulose-coated beads and granules have also demonstrated the ability to 
absorb pressure and hence protect the coating from Fracture during compression.  
 High-viscosity grades of ethyl cellulose are used in drug microencapsulation.  
 Release of a drug from an ethyl cellulose microcapsule is a function of the 
microcapsule wall thickness and surface area. 
  In tablet formulations, ethyl cellulose may additionally be employed as a binder, the 
ethyl cellulose being blended dry or wet granulated with a solvent such as ethanol 
(95%). 
 Ethyl cellulose produces hard tablets with low friability, although they may 
demonstrate poor dissolution. Ethyl cellulose has also been used as an agent for 
delivering therapeutic agents from oral (e.g. dental) appliances. 
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 In topical formulations, ethyl cellulose is used as a thickening agent in creams, 
lotions, or gels, provided an appropriate solvent is used. Ethyl cellulose has been 
studied as a stabilizer for emulsions. Ethyl cellulose is additionally used in cosmetics 
and food products. 
 
Table 5.2.: Uses of ethyl cellulose. 
 
Use Concentration(%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
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                                  MAGNESIUM STEARATE                 (Raymond C.R., et al., 2009) 
Nonproprietary names: 
BP : Magnesium stearate 
JP : Magnesium stearate 
PhEur : Magnesii stearas 
USPNF : Magnesium stearate  
Synonyms:    
          Magnesium octa decanoate, Magnesium salt. 
Chemical name and CAS registry number 
Octa decanoic acid magnesium salt [557-04-0] 
Functional category : Tablet and capsule lubricant 
Empirical formula :   C36H70MgO4 
Molecular weight :  591.3 
Structure: 
                                   CH3 (CH2)16 COO                           
                                                                             Mg    
                                    CH3 (CH2)16 COO 
Description: 
           It is a fine, white, precipitated or milled, impalpable powder of low bulk density and 
having a faint odor of stearic acid, characteristic taste.  
 Solubility: 
          It is insoluble in water, ethanol and ether. It can slightly soluble in warm ethanol and 
benzene.        
 Stability and storage conditions: 
  Stable, Store in a well closed container in a cool, dry place.                    
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LACTOSE MONOHYDRATE 
Synonyms : Milk sugar; Pharmatose; Lactochem; Lactohale; Prismalac;      
Saccharum lactis 
Category  : Diluent for dry powder, tablet and capsule diluents 
 Chemical Name : o-ß-D-Galactopyranosyl- (1→4) –α-D-glucopyranose monohydrate 
Structure: 
 
Empirical Formula : C12H22O11. H2O 
Molecular Weight : 360.31
 
      Description : It is a crystalline powder which is white to off white in color,            
odorless, weet tasting. 
Density  : 1.54 g/cm3 
Melting Point  : 201-202ºC 
Moisture Content : It contains up to 1 % w/w water 
Stability  : Lactose may develop a brown coloration on storage 
Storage  : It is stored in well closed container in a cool and dry place 
Incompatibilities : Incompatible with amino acid, aminophyllines. 
 
Sustained release matrix tablets of gliclazide               Drug and Excipients profile 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  58 
 
             POLYVINYL PYRROLIDINE 
Synonym: 
Plasdone K-30, Luviskol K30, Plasdone, Povidone, PVP P, PVP-K 30; PVP; 
Polyvinylpyrrolidone;   Poly  [1-(2-oxo-1-pyrrolidinyl)  ethylene);   Povidone  K-30; 
Poly(n-vinlybutyrolactam);Poly(1-vinylpyrrolidinone); 
Chemical Name: Poly (1-vinyl-2-pyrrolidinone) 
 
Chemical Formula: (C6H9NO)n 
 
Chemical structure: 
 
 
 
Physical state and appearance: Solid. ( Powdered solid.) 
 
Odor: Odorless. 
 
Molecular Weight: (111.14) n g/mole 
 
Color: Creamy White. 
 
Boiling Point: 90°C (194°F) - 93 C 
 
Melting Point: 13.9°C (57°F) 
 
Specific Gravity: Density: 1.23 - 1.29(Water = 1) 
 
Incompatibility with various substances: Reactive with oxidizing agents 
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Solubility: 
 
 Soluble in cold water.  
 Soluble in water giving a colloidal solution. 
 Soluble  in  chloroform,  alcohol,  chlorinated  hydrocarbons,  amines, nitro 
 paraffin’s, lower weight fatty acids.  
 
Specification: 
1. Application: PVP K series  can be used as  film forming agent, viscosity-
enhancement agent,  lubricator and adhesive. They are the key component of hair sprays, 
mousse, gels and lotions & solution. They are also convenience assistant in skin  care  
product,  hair-drying   reagent,  shampoo,  eye  makeup,  lipstick, deodorant, sunscreen and 
dentifrice. 
 2.Pharmaceutical:  Povidone K 30 and K 25 is a new and excellent pharmaceutical 
excipient. It is mainly  used  as  binder  for  tablet,  dissolving  assistant  for  injection,  flow 
assistant for capsule,  dispersant for liquid medicine and pigment, stabilizer for enzyme 
and heat sensitive drug, co precipitant for poorly soluble drugs, lubricator  and  antitoxic  
assistant  of  eye  drug.   PVP  has  been  used  as excipients in more than one hundred 
drugs. 
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COLLOIDAL SILICON DIOXIDE 
Synonyms: Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica 
Chemical name: Silica 
Empirical formula: SiO2 
Molecular Weight: 60.08 
Structure: 
 
Description: It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous 
powder 
Melting point: 16000C 
Solubility:  Practically  insoluble  in  organic  solvents,  water,  and  acids,  except 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. 
Incompatibilites: Incompatible with diethylstilbestrol preparations. 
Stabilities  and  Storage  condition:  Colloidal  silicon  dioxide  is  hygroscopic  but 
adsorbs large quantities of water without liquefying. When used in aqueous systems at 
a pH 0–7.5, colloidal silicon dioxide is effective in increasing the viscosity of a 
system. Colloidal silicon dioxide powder should be stored in a well-closed container 
Application: Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and 
food products. Colloidal silicon dioxide is also used to stabilize emulsions and as a 
thixotropic thickening and suspending agent in gels and semisolid preparations. In 
aerosols, other than those for inhalation, colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray 
nozzles. Colloidal silicon dioxide is also used  as a tablet disintegrant  and as  an 
adsorbent dispersing agent for liquids in powders. 
Sustained release matrix tablets of gliclazide               Drug and Excipients profile 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  61 
 
ISOPROPYL ALCOHOL 
Structure: 
 
 
Synonyms Di methyl carbinol,  isopropanol , 2-propanol. 
Empirical formula C3 H8 O 
Molecular wt 60.1 
Description Clear , colorless, mobile, volatile, flammable liquid with 
characteristic, spirituous odor& slightly bitter taste 
Functional category Disinfectant,  solvent 
Solubility Miscible with benzene, chloroform,   ethanol. 
Soluble in acetone 
Insoluble   in salt solutions. 
 Storage conditions Store in a airtight container in a cool & dry place 
Incompatibility Incompatible with H2O2& Nitric acid. 
Salting out from  aqueous preparations by adding sodium salts 
Applications Tablets - Film forming agent & Granulating agent 
70%v/v used as disinfectant 
Not recommended for oral use 
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                             6. MATERIALS AND EQUIPMENTS 
 
6.1. Materials used: 
Table 6.1: List of materials with source 
S.No. Name of Ingredients Name of supplier 
1 Gliclazide Sunglow pharmaceuticals, Puducherry. 
2 HPMC K100M Tristar formulations Pvt. Ltd., Puducherry. 
3 Ethyl cellulose Tristar formulations Pvt. Ltd., Puducherry. 
4 Polyvinyl pyrrolidone K30 Nickon laboratories Pvt. Ltd., Puducherry. 
5 Magnesium stearate Loba chemie Pvt.Ltd., Mumbai. 
6 Lactose Loba chemie Pvt.Ltd., Mumbai. 
7 Aerosil S d fine-chem limited, Mumbai. 
8 Isopropylalcohol Qualigens fine chemicals, Mumbai. 
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6.2. Equipments used: 
Table 6.2: List of equipments with model/make 
S.No. Equipment Model/ Make 
1 Electronic balance Shimadzu BL-220H, Japan. 
2 Bulk density apparatus Indolabs VTAP/MATIC-II, Chennai. 
3 Standard sieves Jayant scientific, India. 
4 Hot air oven Precision scientific Co., Chennai. 
5 
Sixteen punch tablet compression 
machine 
Cadmach, Ahmadabad, India. 
6 Friability apparatus Veego scientific VFT-DV, Mumbai. 
7 Hardness tester Monsanto 
8 Vernier caliper Indolabs, Mitutoyo. 
9 Humidity chamber Labtech, Ambala. 
10 USP dissolution test apparatus Type I Veego scientific VDA-8DR, Mumbai. 
11 UV-Visible spectrophotometer 
Elico-SL 159 UV-Visible 
spectrophotometer, Japan. 
12 FTIR spectrophotometer Shimadzu, Japan. 
13 Differential scanning calorimeter Shimadzu, Japan. 
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7. EXPERIMENTAL WORK 
7.1. Preformulation study: 
 Preformulation testing is an investigation of physical and chemical properties 
of a drug substance alone. It is the first step in rational development of dosage form. 
7.1.1. Identification of drug: 
7.1.1.1. Identification by FTIR spectroscopy:     (IP, 2007; Skoog D.A., et al., 2004)     
 Gliclazide discs were prepared by pressing the Gliclazide with potassium 
bromide and the spectra ranges between 4000 to 600 cm-1 was obtained under the 
operational conditions. The absorption maximums in spectrum obtained with the 
substance being examined correspond in position and relative intensity to those in the 
reference spectrum.  
7.1.1.2. Identification by melting point:                             (IP, 2007)                                                
Melting point of the drug was determined by capillary tube method. 
7.1.2. Physicochemical parameters: 
7.1.2.1. Organoleptic properties:     (Lachman L., et al., 1991; Banker G.S., et al., 
2009)   
The color, odor and taste of the drug were recorded using descriptive 
terminology. 
7.1.2.2. Solubility study:                                                        (IP, 2007) 
It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response. The solubility of drug was recorded by using various descriptive 
terminology specified in Indian Pharmacopoeia, 2007. 
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7.1.3. Analytical methods:  
7.1.3.1. Determination of absorption maximum in 0.1 N HCl:                 
 A stock solution of  Gliclazide was prepared by dissolving 100 mg of drug in 
0.1 N HCl and final volume was made to 100 ml. From the stock solution, 1 ml was 
pipettted out into 100 ml volumetric flask to obtain concentration of 10µg/ml. The 
solution was scanned in the range of wavelength of 200 to 400 nm region on 
shimadzu- 1700 pharmaspec UV- Visible spectrophotometer.  
 
7.1.3.2.  Preparation of standard graph of Gliclazide using phosphate buffer pH 7.4: 
 
           Beer’s law is obeyed in the concentration range of 5 – 25 mcg/ml. 
 
Method:- 
 
50  mg  of  Gliclazide  was  accurately  weighed  into  100ml  volumetric  
flask  and dissolved in  phosphate buffer pH 7.4. The volume was made up to 
100ml to get a concentration of (0.5 mg/ml.) stock solution- I. From this, 1 ml 
was withdrawn and diluted to 10 ml to get a concentration of (25 µg/ml) stock 
solution -II. 
 
Scanning of Drug:- 
 
From stock solution-II (SS-II), 4 ml was withdrawn and the volume was 
made up to 10 ml with phosphate buffer pH 7.4 to get a concentration of 10 µg/ml. 
UV scan range was taken between the wavelengths 200-400 nm. It gave a peak at 
226.5 nm and 225.5 nm and the same was selected as λmax for Gliclazide. 
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7.1.3.3. Preparation of standard curve of Gliclazide  in 0.1N HCl:         
            A stock solution of gliclazide was prepared by dissolving 100 mg of drug in 
0.1 N HCl and final volume was made to 100 ml to give a solution concentration 1000 
µg/ml. From the stock solution, 10 ml was pipettted out into 100 ml volumetric flask 
to obtain concentration of 100µg/ml. From the standard stock solution of gliclazide, 
appropriate aliquots of 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 ml were pipetted out into 50 
ml volumetric flask and final volume was made with 0.1 N HCl. To obtained 
concentration of 5, 10, 15, 20, 25 and 30 µg/ml. Absorbance spectra of each solution 
against 0.1 N HCl as blank were measured at 281 nm using Elico-SL 159 UV-Visible 
spectrophotometer.   
7.1.3.5. Determination of Percentage purity of Drug:        
           An accurately weighed 100 mg of Gliclazide was dissolved in 100 ml of 
methanol followed by mixing for 10 minutes. From the stock solution, 10 ml was 
pipettted out into 100 ml volumetric flask to obtain concentration of 100µg/ml.  The 
solution was filtered through a 0.45μ membrane filter. From the above solution, 
aliquots of 0.6 ml were transferred to 10 ml volumetric flasks and final volume was 
made to 10 ml with methanol and the absorbance of resultant solution was measured 
by using Elico-SL 159 UV-Visible spectrophotometer at 271.5 nm using methanol as 
blank. 
7.1.4. Determination of drug-polymer compatibility:                 (Aulton M.E., 2007) 
 Differential scanning calorimetry, Fourier transforms infrared spectroscopy 
studies were used for the evaluation of physicochemical compatibility and interaction, 
which helps in the prediction of interaction of the drug and polymers. Each polymer 
used in the formulations was blended with the drug levels that are realistic with 
Sustained release matrix tablets of gliclazide                                   Experimental work 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  67 
 
respect to the final dosage form. Each polymer was thoroughly blended with drug to 
increase drug- polymer molecular contacts to accelerate the reactions if possible. 
7.1.4.1. Fourier transform infrared spectroscopy:           (Althaf A.S., et al., 2010; 
Raju M.,et al., 2010; Silverstein R.M., 2003)         
            FTIR studies are very helpful in the evaluation of drug polymer interaction 
studies. If there is any incompatibility between the drug and polymer, these can be 
predicted by changes in the functional peaks. Infrared spectrum of gliclazide was 
determined on Fourier transform infrared spectrophotometer using potassium bromide 
dispersion method. The base line correction was done using dried potassium bromide. 
Then the spectrum of dried mixture of drug and various polymers were thoroughly 
mixed with potassium bromide. The crushed powders were compressed using a 
hydraulic compactor at approximately 20,000 pounds under vacuum for 3 minutes. 
FTIR instrument were performed under nitrogen atmosphere at a flow rate of 50 
standard cubic feet per hour. Spectral scanning was conducted from 4000 to 400 cm-1 
at a resolution of 4 cm-1 by using Shimadzu (Japan) FTIR spectrophotometer.  
7.1.4.2. Differential scanning calorimetry:      (Raju M.,et al., 2010; Willard H.H., 
et al., 2008) 
            Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC analyses of pure drug, drug + HPMC K100M and drug + ethyl cellulose were 
carried out using Shimadzu to evaluate any possible drug-polymer interaction. The 2 
mg sample were heated in a hermetically sealed aluminum pans in the temperature 
range of 25-300ºC at heating rate of 10ºC /min under nitrogen flow of 30 ml/min. 
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7.1.5. Formulation of Gliclazide  sustained release matrix tablets:     (panchal 
v.n, et al., 2011)                                                
  All the ingredients mentioned in Table 7.1 were pre-weighed and passed 
through mesh #60 separately. The drug and polymer were blended first in mortar and 
pestle then the remaining ingredients are added in that and blended for 15 minutes 
and the blend is finally passed through mesh #20 and used for evaluation of flow 
characteristic. 
                          Table 7.1: Composition of gliclazide SR matrix tablets 
Ingredients(mg) LF1 LF2 LF3 LF4 LF5 LF6 LF7 LF8 LF9 
Gliclazide 60 60 60 60 60 60 60 60 60 
HPMC K100M 35 70 105 - - - 17.5 35 52.5 
Ethyl cellulose - - - 35 70 105 17.5 35 52.5 
Lactose 240 205 170 240 205 170 240 205 170 
Polyvinyl 
pyrrolidone-k30 
10 10 10 10 10 10 10 10 10 
Magnesium 
stearate 
4 4 4 4 4 4 4 4 4 
Aerosol 1 1 1 1 1 1 1 1 1 
Isopropyl alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
Total weight 350 350 350 350 350 350 350 350 350 
All the quantities are expressed as mg per tablet. 
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7.1.6. Evaluation of pre-compression blend: 
7.1.6.1. Angle of repose:                                          (Lachman L., et al., 1991) 
The angle of repose was determined by the funnel method. An accurately 
weighed powder was taken in a funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter 
of the powder cone was measured. The angle of repose was calculated using the 
following equation. 
 
Where ‘h’ and ‘r’ are the height and radius respectively of the powder cone. 
Table 7.2: Standard values of angle of repose (°) 
S. No. Flowability  Angle of repose  
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
          * Adding glidant for improving flow 
7.1.6.2. Loose bulk density:                                       (Lachman L., et al., 1991) 
An accurately weighed powder blend from each formula was lightly shaken to 
break any agglomerates formed and it was introduced in to a measuring cylinder. The 
volume occupied by the powder was measured which gave bulk volume. The loose 
bulk density of powder blends was determined using the following formula. 
Loose bulk density = Total weight of powder / Total volume of powder 
Sustained release matrix tablets of gliclazide                                   Experimental work 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  70 
 
7.1.6.3. Tapped bulk density:                                       (Lachman L., et al., 1991) 
An accurately weighed powder blend from each formula was lightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in volume was noted which 
gave the tapped volume. The tapped bulk densities of powder blends were determined 
using the following formula. 
   Tapped bulk density= Total weight of powder / Total volume of tapped powder 
7.1.6.4. Hausner’s ratio:                                                    (Aulton M.E., 2007) 
It is related to interparticulate friction and could be used to predict powder 
flow properties.   Hausner’s ratio was determined by following equation,    
Hausner’s Ratio = Tapped bulk density / Loose bulk density 
  A Hausner ratio less than 1.25 indicates good flow while greater than 1.5 
indicates poor flow. 
7.1.6.5. Carr’s compressibility index:                             (Aulton M.E., 2007) 
It is a simple index that can be determined on small quantities of powder. The 
compressibility indices of the powder blends was determined using following 
formula, 
Carr’s compressibility index (%) = [(TBD-LBD)/ TBD] x100 
Relationship between % compressibility and flowability is shown in the table 7.3.  
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Table 7.3: Standard values of Carr’s index 
S. No. Carr’s index Type of flow 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair to passable 
4 23-35 Poor* 
5 33-38 Very poor* 
6 >40 Extremely poor* 
* May be improved by glidant 
7.2. Preparation of SR Matrix Tablets:      
Direct compression method: 
All the ingredients metioned in Table 7.1 were passed through Sieve no. 60 
mesh separately and collected. Ingredients were mixed in geometrical order and 
thoroughly mixed for 15 minutes to get a uniform mixture and the blend is finally 
passed through mesh #20. LACTOSE and magnesium stearate were added to the 
powder mixture and compressed on a 16- station rotary tablet compression machine 
using 11mm round, biconcave punches.   
The drug polymer ratio was developed to adjust drug release as per theoretical 
release profile and to keep total weight of tablet constant for all the fabricated batches 
under experimental conditions of preparations. The total weight of the matrix tablets 
was 350 mg with different drug polymer ratios. 
In the formulations prepared, the release retardants included were 
hydroxypropyl methylcellulose (HPMC K100M), and ethylcellulose.lactose is used as 
diluent. Magnesium stearate 1% and aerosil were used as lubricant and glidant.  
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7.3. Evaluation of gliclazide sustained release matrix tablets:  
7.3.1. Appearance:                                                  (Lachman L., et al., 1991) 
The tablets were visually observed for capping, chipping and lamination. 
7.3.2. Dimension (Thickness and Diameter):          (Lachman L., et al., 1991)                          
 The thickness and diameter of tablets were important for uniformity of tablet 
size. The thickness and diameter of the tablets was determined by using Vernier 
caliper. Ten tablets from each type of formulation were used and average values were 
calculated.  
7.3.3. Tablet hardness:                                          (Lachman L., et al., 1991) 
For each formulation, the hardness of 10 tablets was determined using the 
Monsanto hardness tester. The tablet was held along its oblong axis in between the 
two jaws of the tester. At this point, reading should be zero kg/cm2. Then constant 
force was applied by rotating the knob until the tablet fractured. The value at this 
point was noted in kg/cm2.  
7.3.4. Percent friability:                                           (Lachman L., et al., 1991) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre weighed tablets was placed in Roche friabilator which 
was then operated for 100 revolutions. The tablets were then dedusted and reweighed. 
A loss of less than 1 % in weight is generally considered acceptable. Percent friability 
(% F) was calculated as follows.  
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7.3.5. Weight variation:                                  (IP, 2007; Lachman L., et al., 1991) 
To find out weight variation 20 tablets of each formulation were weighed 
individually using an electronic balance, average weight was calculated and 
individual tablet weight was then compared with average value to find the deviation 
in weight. The test was performed according to the official method. 
Weight variation importance during tablets compression section, each and 
every time intervals we must check the weight of tablet. If we are not maintaining the 
weight variation means it will give the deviation of drug content as well as yield of 
tablets.  
 Table 7.4: Specifications of % weight variation allowed in tablets as per Indian 
Pharmacopoeia 
S. No. Average weight of tablets (mg) 
Maximum percent deviation 
allowed (%) 
1 80 or less 10 
2 More than 80 but less than 250 7.5 
3 More than 250 5 
 
7.3.6. Drug content:                                                              
The drug content in each formulation was determined by triturating 20 tablets 
and powder equivalent to 100 mg of gliclazide was transferred into a 100 ml standard 
volumetric flask. Then added 50ml of pH 7.4  phosphate buffer solution. It was gently 
shaken for 15 minutes. Then made upto the mark with pH 7.4 phosphate buffer 
solution. The solution was filtered through a whatmann filter paper, diluted suitably 
and the absorbance of resultant solution was measured by using Elico-SL 159 UV-
Visible spectrophotometer at 225.5 nm using pH 7.4 phosphate buffer as blank. 
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7.3.7. In vitro release studies:                                     
The release rate of gliclazide from matrix tablets was determined using United 
States Pharmacopoeia dissolution testing apparatus I (Basket method; Veego 
Scientific VDA-8DR, Mumbai, India). The dissolution test was performed at 100 rpm 
using 900 ml of pH 1.2  for the first 2 hrs and phosphate buffer pH 7.4 from 2-10 hrs 
at 37 ± 0.5°C. A sample (5 ml) of the solution was withdrawn from the dissolution 
apparatus hourly and the samples were replaced with fresh dissolution medium. The 
samples were filtered through a 0.45μ membrane filter and diluted suitably. 
Absorbance of these solutions was measured at 225.5 nm using Elico-SL 159 UV-
Visible spectrophotometer. For each formulation, the experiments were carried out in 
triplicate. The release data were analyzed to study the release kinetics using zero 
order, first order and matrix, korsmeyer-peppas equations by using PCP disso V3 
software. 
7.3.8. Kinetics of in vitro drug release:   (Brahmankar D.M. and Jaiswal S.B., 2009; 
Harris S.M., et al., 2006) 
To study the release kinetics of in vitro drug release, the data was applied to 
kinetic models such as zero order, first order, higuchi and korsmeyer- Peppas. 
 Zero order 
 
Where     K0 - Zero-order rate constant expressed in units of concentration/time   
                 t - Time in hrs. 
 First order 
 
Where   C0 - Initial concentration of drug, 
               K - First order constant and t - Time in hrs.  
C = K0t                                                                                                              
LogC = LogC0 – Kt / 2.303                                                                            
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 Higuchi 
 
Where   Qt - Amount of the release drug in time t, 
               K- Kinetic constant and t- is time in hrs 
 Korsmeyer Peppas 
 
Where, Mt - represents amount of the released drug at time t,  
           M∞- Overall amount of the drug (whole dose) released after 12 hrs  
           K- Diffusion characteristic of drug/ polymer system constant  
           n- Diffusion exponent that characterizes the mechanism of release of drug.  
Table 7.5: Diffusion exponent and solute release mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n <0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n>0.89 Super case-II transport 
 
7.4. Stability study:        (Carstensen J.T., et al., 2008; Manavalan R., et al., 2008)  
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
Qt = Kt1/2                                                                                                          
Mt / M∞ = Kt n                                                                                             
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requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted.  
ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25 C ± 2 C at 60% RH ± 5% for 12 Months  
 Accelerated Testing: 40 C ± 2 C at 75% RH ± 5% for 6 Months  
In present study the selected formulation LF3 exposure  up to 3 months 
stability studies at accelerated condition (40 C ± 2 C
 
at 75% RH ± 5% RH) to find 
out the effect of aging on hardness, drug content and in vitro drug release.  
Stability studies were carried out at accelerated condition (40 C ± 2 C
                    
at 75% RH ± 5% RH) for the optimized formulation LF3. The matrix                  
tablets were stored at 40 C ± 2 C at 75% RH ± 5% RH for accelerated         
temperature in closely packed with aluminium foil for 3 months. The                
samples were withdrawn after periods of 1st month, 2nd month and 3rd month. The 
samples were analyzed for its hardness, drug content and in vitro drug release.   
  
 
RESULTS 
AND  
DISCUSSION
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                        8. RESULTS AND DISCUSSION 
 
8.1. Preformulation parameters: 
8.1.1. Identification of drug: 
8.1.1.1. Identification by FTIR spectroscopy: 
The FTIR spectrum of gliclazide was shown in Figure 8.1 and the 
interpretations of FTIR frequencies were showed in Table 8.1. 
 
Figure 8.1: FTIR spectrum of gliclazide 
 Interpretation of FTIR Spectrum: 
Major functional groups present in gliclazide shows characteristic peaks in 
FTIR spectrum. Table 8.1 shows peaks observed at different wave numbers and the 
functional group associated with these peaks. The major peaks are identical to 
functional group of gliclazide. Hence, the sample was confirmed as gliclazide. 
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Table 8.1: Characteristic frequencies in FTIR spectrum of gliclazide 
Wave No.(cm-1) Functional group 
3447.78 N-H stretching 
2931.44 CH3 asymmetric stretching 
2867.38 CH3 absorption 
1710.23 C-O stretching 
1639.47 NH2 deformation 
1596.58 C=C stretching 
1348.07 C-C stretching 
1164.24 C-N stretching 
 
8.1.1.2. Melting point: 
Melting point of gliclazide sample was found to be 180.40C. The reported 
melting point for gliclazide was in range of 180 to 1820C. Hence, experimental values 
are in good agreement with official values. 
8.1.2. Physicochemical parameters of drug: 
8.1.2.1. Organoleptic properties: 
Odour     :  Odorless  
Colour    :  A White (or) almost white powder 
Taste    :  Bitter taste 
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8.1.2.2. Solubility study: 
Table 8.2: Solubility of gliclazide in different solvents 
 
8.1.3. Analytical methods: 
8.1.3.1. Determination of absorption maximum in 0.1 N HCl: 
                   The absorption maximum for gliclazide was found to be 281 nm. 
 
Figure 8.2: λ max observed for gliclazide in 0.1N HCl 
 
Name of solvents Solubility 
Distilled water  InSoluble 
Methanol Sparingly soluble 
0.1N HCl Freely Soluble 
Dichloro methane (or) methylene 
chloride 
Freely Soluble 
Phosphate buffer (pH 7.4) Freely Soluble 
Acetone Soluble 
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8.1.3.2. Determination of absorption maximum in pH 7.4 phosphate buffer:     
                The absorption maximum of gliclazide was found to be 225.5 nm. 
 
Figure 8.3: λ max observed for gliclazide in pH 7.4 phosphate buffer. 
8.1.3.3. Preparation of standard curve of gliclazide in 0.1 N HCl: 
UV absorption spectrum of gliclazide in 0.1N HCl showed λ max at 281 nm. 
Absorbance obtained for various concentrations of gliclazide in 0.1N HCl are given in 
Table 8.3. The curve of absorbance versus concentration for gliclazide was found to 
be linear in the concentration range of 0–30 μg/ ml. The drug obeys Beer- Lambert’s 
law in the range of 0–30 μg/ ml. 
Table 8.3: Concentration and absorbance of gliclazide in 0.1N HCl 
S. No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 5 0.304 
3 10 0.597 
4 15 0.901 
5 20 1.173 
6 25 1.472 
7 30 1.760 
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Figure 8.4: Calibration curve of gliclazide in 0.1N HCl 
 
Table 8.4: Calibration parameter values in 0.1 N HCl 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m)  0.0585 
3 Intercept (c) 0.0090 
 
8.1.3.4. Preparation of standard curve of gliclazide in pH 7.4 phosphate buffer: 
UV absorption spectrum of gliclazide in pH 7.4 showed λ max at 225.5 nm. 
Absorbance obtained for various concentrations of gliclazide in pH 7.4 are given in 
Table 8.5. The curve of absorbance versus concentration for gliclazide was found to 
be linear in the concentration range of 0–30 μg/ ml. The drug obeys Beer- Lambert’s 
law in the range of 0–30 μg/ ml. 
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Table 8.5: Concentration and absorbance of gliclazide in pH 7.4 phosphate buffer 
S. No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 5 0.210 
3 10 0.409 
4 15 0.592 
5 20 0.788 
6 25 0.981 
7 30 1.183 
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     Figure 8.5: Calibration curve of gliclazide in pH 7.4 phosphate buffer 
 Table 8.6: Calibration parameter values in pH 7.4 phosphate buffer 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m)  0.0391 
3 Intercept (c) 0.0086 
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8.1.3.5. Percentage purity of drug: 
The percentage purity of drug was calculated by using calibration curve 
method. The percentage purity of drug was found in official limits. 
Table 8.7: Percentage purity of gliclazide in pure drug 
The reported percentage purity for gliclazide in IP 2007 is 97 to 102%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No. Percentage purity (%) 
Average percentage  
purity (%) 
1 99.79  
100.13 ± 0.30 2 100.29 
3 100.33 
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8.1.4. Compatibility testing of drug with polymer: 
  Compatibility of drug and polymers was found to be as following methods 
such as Fourier transform infrared spectroscopy and differential scanning calorimetry. 
8.1.4.1. Fourier transform infrared spectroscopy: 
The FTIR spectrums of gliclazide with different polymers used in formulation 
are shown in Figures 8.6, 8.7 and Table 8.8. 
                      
Figure 8.6: FTIR spectrum of gliclazide with  HPMC K100M 
 
Figure 8.7: FTIR spectrum of gliclazide with ethyl cellulose 
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     Table 8.8: FTIR peak observed for gliclazide with different polymers used in                
                     formulations. 
Functional groups 
Peaks observed [Wave No. (cm-1)]   
GLI + 
HPMC 
K100M 
GLICLAZIDE GLI + Ethyl 
cellulose 
N-H stretching 3444.94 3447.78 3454.55 
CH3 asymmetric 
stretching 2932.91 2931.44 2932.16 
CH2 absorption 2867.06 2867.38 2867.23 
C-O stretching 1710.17       1710.23 1710.17 
NH2 deformation 1638.46 1639.47 1637.13 
C=C stretching 1598.55 1596.58 1598.99 
C-C stretching 1347.63 1348.07 1348.19 
C-N stretching 1163.95 1164.24 1164.29 
 
According to Table 8.8 and Figures 8.1, 8.6, and 8.7, FTIR spectrum showed 
that there was no major difference in peak when compared between pure drug of 
gliclazide and gliclazide with different polymers. Therefore it could indicate that there 
was no incompatibility between drug and different polymers. 
8.1.4.2. Differential scanning calorimetry: 
The compatibility and interactions between drug and polymers were checked 
using differential scanning calorimetry and the results were shown in Figures 8.8, 8.9 
and 8.10. 
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Figure 8.8: DSC thermal analysis of gliclazide 
 
 
Figure 8.9: DSC thermal analysis of gliclazide + HPMC K100M 
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Figure 8.10: DSC thermal analysis of gliclazide + ethyl cellulose 
According to Figures 8.9 to 8.12 and Table 8.9, DSC thermogram showed that 
there was no major difference in onset temperature, end set temperature and peak 
temperature when compared with pure drug thermogram. Therefore it could indicate 
that there was no incompatibility between drug and different polymers. 
Table 8.9: DSC thermogram parameters of gliclazide with various polymers 
S. No. DSC thermogram 
Onset 
temperature 
(°C) 
Peak 
temperature 
(°C) 
End set 
temperature 
(°C) 
1 Gliclazide 180.42 182.61 184.62 
2 
Gliclazide + HPMC 
K100M 
178.70 181.30 183.81 
3 
Gliclazide + 
Ethylcellulose 
177.75 180.27 184.59 
 
 
Sustained release matrix tablets of gliclazide                              Results and discussion 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  88 
 
8.2. Evaluation of powder blends: 
The blended powders of different formulations were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index and Hausner 
ratio. The results of these evaluations were as follows: - 
8.2.1. Angle of repose: 
            Angle of repose ranged from 23.20°± 0.61 to 24.49°± 0.36. The results were 
found to be below 25o and hence the blend was found to have excellent flowability. 
(Table No. 8.10). 
 
Table 8.10: Flow characteristics of powder blends 
Formulation 
Code 
Angle of 
repose (o)* 
Loose bulk 
density 
(g/ml)* 
Tapped 
bulk 
density 
(g/ml)* 
Hausner 
ratio* 
Carr’s 
index (%)* 
GF1 24.19±0.98 0.638±0.00 0.730±0.00 1.13±0.00 12.147±0.30 
GF2 24.48±0.17 0.538±0.00 0.616±0.06 1.09±0.02 10.333±0.33 
GF3 23.36±0.98 0.481±0.01 0.547±0.04 1.10±0.00 9.736±1.14 
GF4 23.44±0.73 0.547±0.00 0.721±0.02 1.24±0.10 14.505±2.20 
GF5 24.05±0.19 0.572±0.00 0.682±0.00 1.22±0.03 16.256±0.61 
GF6 23.30±0.17 0.616±0.00 0.778±0.00 1.21±0.00 16.582±0.09 
GF7 23.93±0.77 0.561±0.01 0.691±0.00 1.20±0.06 13.586±2.66 
GF8 23.20±0.61 0.590±0.01 0.646±0.00 1.11±0.00 12.038±1.50 
GF9 24.49±0.36 0.602±0.01 0.636±0.00 1.16±0.17 15.236±0.47 
*All the values were expressed as mean± SD, n=3 
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8.2.2. Loose bulk density and tapped bulk density: 
            Bulk and tapped densities are used for the measurement of Compressibility 
index. The LBD and TBD ranged from 0.481 ± 0.01 to 0.638 ± 0.00 g/ml; and 0.547 ± 
0.04 to 0.778 ± 0.00 g/ml respectively. (Table No. 8.10). 
8.2.3. Compressibility index (Carr’s index): 
 The compressibility index (%) ranged from 9.736 ± 1.14 to 16.582 ± 0.09 
(Table No.8.10). The blend was found to have excellent flowing property as the result 
were found to be below 15%.  
 8.2.4. Hausner ratio: 
The Hausner ratio ranged from 1.09 ± 0.02 to 1.24 ± 0.10, (Table No.8.10). 
The result indicates the free flowing properties of the powders. 
8.3. Evaluation of sustained release matrix tablets: 
8.3.1. Appearance: 
Surface nature of tablets was observed visually and it was concluded they did 
not show any defects such as capping, chipping and lamination.  
8.3.2. Physico-chemical characteristics:  
The physical characteristics of gliclazide matrix tablets (GF1 toGF9) such as 
thickness, diameter, hardness, friability, weight variation and drug content were 
determined and the results were shown in table 8.11. 
8.3.2.1. Dimension (Thickness and Diameter): 
 The size (diameter) of the tablets was found to be in the range from 
11.17±0.01 mm to 11.20 ± 0.01 and thickness between 4.32 ± 0.06 to 4.58 ± 0.04 mm. 
8.3.2.2. Tablet hardness:  
 The hardness of tablets was found to be in the range from 5.1 ± 0.10 kg/cm2 to 
6.3 ± 0.10 kg/cm2. This indicates good mechanical strength of tablet. 
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8.3.2.3. Percent friability: 
Percentage friability of all the formulations was found to be in the range from 
0.418±0.04 to 0.846±0.09 %. This indicates good handling property of the prepared 
matrix tablet 
Table 8.11: Physico-chemical parameters of gliclazide matrix tablets  
F. 
Code 
Dimension 
Hardness 
(kg/cm2) 
Friability 
(%) 
Weight 
variation 
(mg) 
Drug 
content 
(%w/w) 
Diameter 
(mm) 
Thickness 
(mm) 
GF1 11.20±0.01 4.44±0.02 5.2±0.10 0.704±0.07 348.15±1.47 99.00±1.55 
GF2 11.19±0.02 4.37±0.06 5.5±0.30 0.774±0.07 348.70±2.42 101.00±2.20 
GF3 11.20±0.01 4.57±0.06 5.1±0.10 0.846±0.09 348.70±2.42 99.55±1.10 
GF4 11.19±0.01 4.32±0.06 5.8±0.10 0.634±0.05 347.05±3.25 101.00±2.20 
GF5 11.17±0.01 4.34±0.07 6.1±0.26 0.677±0.06 347.10±3.88 99.75±0.55 
GF6 11.17±0.04 4.40±0.09 5.2±0.20 0.418±0.04 347.05±3.25 102±2.20 
GF7 11.19±0.01 4.58±0.04 5.9±0.43 0.705±0.10 347.30±3.10 99.50±3.00 
GF8 11.19±0.01 4.54±0.02 5.2±0.17 0.805±0.07 347.70±2.31 99.23±1.13 
GF9 11.18±0.01 4.46±0.06 6.3±0.10 0.631±0.06 348.45±2.06 98.56±1.12 
All the values were expressed as mean ± SD, n=3 
8.3.2.4. Weight variation: 
A tablet is designed to contain a specific amount of drug. When the average 
weight of the tablet is 400 mg, the pharmacopoeial limit for percentage deviation is ± 
5%. The percentage deviation from average tablet weight for all the tablet was found 
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to be within the specified limits and hence all formulations complied with the test for 
weight variation according to the pharmacopoeial specifications IP 2007. 
8.3.2.5. Drug content: 
 The drug content of all the formulation was found to be in the range from 
98.56 ± 1.55 to 102 ± 2.20 % w/w, which was within the specified limit as per IP 
2007. 
8.3.3. In vitro dissolution studies: 
Table.8.12: Results of in vitro release studies of gliclazide sustained release            
                   matrix tablets 
 
 
S. No 
Time in 
hours 
Formulation code 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
 
1 
 
 
1 
09.21 
 
±0.11 
12.4 
 
±1.54 
14.5 
±1.04 
16.7± 
 
1.54 
14.4± 
 
1.56 
15.6± 
 
0.45 
9.4 
 
±2.78 
6.81± 
 
0.45 
8.8± 
 
1.54 
 
 
2 
 
 
2 
19.89 
 
±1.23 
36.8 
 
±1.89 
29.3 
 
±2.66 
34.8± 
 
0.61 
38.7 
 
±1.05 
30..4± 
 
0.15 
17.8 
 
±1.96 
13.73 
 
±0.55 
15.7 
 
±1.45 
 
 
3 
 
 
3 
49.30 
 
±2.54 
48.5 
 
±2.54 
37.7 
 
±0.20 
58.6± 
 
0.02 
52.9± 
 
3.51 
38.9± 
 
1.63 
29.6 
 
±0.12 
38.6 
 
±0.56 
26.4 
 
±1.52 
 
 
4 
 
 
4 
75.00 
 
±1.56 
68.4 
 
±1.65 
49.7 
 
±1.53 
79.5± 
 
0.91 
63.3 
 
±1.55 
51.1± 
 
3.55 
47.7 
 
±0.56 
49.2 
 
±0.22 
33.8 
 
±0.01 
 
 
5 
 
 
5 
93.10 
 
±2.57 
79.3 
 
±0.22 
64.2 
 
±2.01 
92.1± 
 
0.78 
71.5 
 
±0.45 
65.3± 
 
2.23 
68.9 
 
±1.56 
56.9± 
 
1.51 
48.1 
 
±0.12 
 
 
6 
 
 
6 
93.30 
 
±0.23 
81.5 
 
±2.55 
76.5 
 
±2.50 
92.6± 
 
0.51 
84.6 
 
±0.61 
77.5± 
 
1.25 
79.3 
 
±3.45 
69.8 
 
±1.02 
57.9 
 
±0.65 
 
 
7 
 
 
7 
93.60 
 
±1.54 
94.0 
 
±0.23 
87.6 
 
±1.21 
93.1± 
 
0.05 
93.8 
 
±0.49 
88.9± 
061 
84.6± 
 
1.56 
76.4 
 
±2.55 
66.6 
 
±0.54 
 
 
8 
 
 
8 
93.90 
 
±2.45 
94.8 
 
±2.55 
95.6 
 
±0.54 
93.9± 
 
0.07 
94.9 
 
±0.61 
96.0± 
 
0.74 
95.0 
 
±1.26 
85.1 
 
±2.16 
78.6 
 
±1.55 
 
 
9 
 
 
9 
94.10 
 
±2.77 
95.4 
 
±2.54 
95.8 
 
±0.26 
94.3 
±048 
95.2 
 
±1.54 
96.2± 
 
0.07 
95.2 
 
±0.16 
97.3 
 
±2.55 
83.5 
 
±0.65 
 
 
10 
 
 
10 
94.30 
 
±2.54 
95.6 
 
±2.54 
96.1 
 
±0.50 
94.6± 
 
0.52 
95.8 
 
±0.91 
96.5± 
 
0.21 
95.5 
 
±1.51 
97.5 
 
±2.16 
98.2 
 
±0.55 
                             
                                 
*All values are expressed as mean ± S.D. n=3 
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 Figure 8.11: In vitro drug release profile of formulation GF1 
 
Figure 8.12: In vitro drug release profile of formulation GF2 
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Figure 8.13: In vitro drug release profile of formulation GF3 
 
Figure 8.14: In vitro drug release profile of formulation GF4 
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Figure 8.15: In vitro drug release profile of formulation GF5 
 
   Figure 8.16: In vitro drug release profile of formulation GF6 
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Figure 8.17: In vitro drug release profile of formulation GF7 
 
 Figure 8.18: In vitro drug release profile of formulation GF8 
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Figure 8.19: In vitro drug release profile of formulation GF9 
   
               Figure 8.20: In vitro drug release profile of formulations  GF1 to GF9. 
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Gliclazide drug was soluble in phosphate buffers and its release from the 
matrix was largely dependent on the polymer swelling, drug diffusion and matrix 
erosion. The concentration of polymer in the matrix tablet was a key factor in 
sustaining the drug release. 
Various sustained release formulations were formulated with HPMC K100M, 
and ethyl cellulose polymer alone; polyvinyl pyrrolidone as binder and lactose was 
used as diluents. 
The variation in drug release was due to different types of polymers and 
different concentrations of polymer in all the nine formulations. It is expected that the 
developed formulations should have the following theoretical drug release profile. 
The drug released from formulation GF1 to GF3 containing HPMC K100M at 
three concentration levels of 10%, 20%, 30% were found to be 94.30 ± 2.54, 95.60 ± 
2.54, and 96.1 ± 0.50 % for gliclazide respectively at the end of 10 hours. It was 
shown in Figures (8.8, 8.9 and 8.10). 
The drug released from formulation GF4 to GF6 containing ethyl cellulose at 
three concentration levels of 10%, 20%, 30% were found to be 94.6 ± 0.50, 95.8 ± 
0.91 and 96.5. ± 0.21% for gliclazide respectively at the end of 10 hours . It was 
shown in Figures (8.11, 8.12 and 8.13). 
The drug released from formulation GF7 to GF9 containing both 
HPMCK100M and ethyl cellulose at three concentration levels of 10%, 20%, 30% 
were found to be 95.5 ± 1.51, 97.5 ± 2.16 and 98.2 ± 0.55% for gliclazide respectively 
at the end of 10 hours. It was shown in Figures (8.14, 8.15 and 8.16). 
The drug release rate from HPMC K100M matrix was found to be less as 
compared to and ethyl cellulose. This might be due to slow hydration of matrix and its 
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property to form a thick gel layer, it’s due to slow erosion of matrix and its property 
which retard the drug release from the tablet for long duration.  
 The overall release rate of gliclazide from ethylcellulose matrices are 
significantly higher than that from HPMC K100M matrices were shown in Figure 
8.17. These results are indicating that HPMC K100M has higher drug retarding ability 
for long duration than ethylcellulose . 
            In addition to concentration of polymer, the type and viscosity of polymer also 
influences drug release. When drug release data obtained from dissolution study of 
different polymers at 10%, 20% and 30% concentration is plotted against time  
respectively, it was observed that low concentration of polymer induces more drug 
release. High concentration of polymer should be retarding the drug release for longer 
period of time.  
            From the above study, the formulation GF9 was concluded as the best 
formulation among all the nine formulation of this series. Hence the formulation GF9 
was selected for further stability study.   
8.3.4. Kinetics of in vitro drug release:  
            In order to investigate the release mechanism, the data were fitted to models 
representing first order, zero order, higuchi and korsmeyer- Peppas. The linear 
regression analysis shown as ‘r’ values in Table 8.22, demonstrated that all the 
formulated tablets follows korsmeyer- Peppas release kinetics. The result obtained 
was shown in Figures 8.21 to 8.29. 
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 Table 8.13: Different kinetic models for gliclazide matrix tablets (GF1 to GF9) 
F. 
Code 
Zero 
order 
First 
order 
Higuchi Korsemeyer- Peppas Best fit 
model 
R2 R2 R2 R2 n 
GF1 0.978 0.918 0.970 0.987 0.720 Peppas 
GF2 0.988 0.895 0.950 0.989 0.749 Peppas 
GF3 0.988 0.927 0.945 0.992 0.759 Peppas 
GF4 0.981 0.849 0.967 0.986 0.698 Peppas 
GF5 0.986 0.890 0.962 0.989 0.731 Peppas 
GF6 0.989 0.899 0.955 0.990 0.743 Peppas 
GF7 0.983 0.888 0.967 0.987 0.726 Peppas 
GF8 0.988 0.892 0.957 0.989 0.736 Peppas 
GF9 0.989 0.922 0.955 0.990 0.759 Peppas 
 
 
 
 
 
                        Figure 8.21: Best fit model (Peppas) of formulation GF1 
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Figure 8.22: Best fit model (Peppas) of formulation GF2 
 
 
 
 
 
Figure 8.23: Best fit model (Peppas) of formulation GF3 
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                   Figure 8.24: Best fit model (Peppas) of formulation GF4 
 
 
 
 Figure 8.25: Best fit model (Peppas) of formulation GF5 
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Figure 8.26: Best fit model (Peppas) of formulation GF6 
 
 
 
Figure 8.27: Best fit model (Peppas) of formulation GF7 
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Figure 8.28: Best fit model (Peppas) of formulation GF8 
 
 
Figure 8.29: Best fit model (Peppas) of formulation GF9 
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 Further, to understand the drug release mechanism, the data were fitted to 
korsmeyer- Peppas exponent equation, when n < 0.45 indicates fickian drug release. 
For 0.45 < n < 0.89 as anomalous diffusion (non-fickian). In the present study also it 
was observed that almost all the formulated tablets followed anomalous diffusion 
mechanism, which indicates the drug release through diffusion coupled with erosion.   
8.4. Stability study: 
After exposure to accelerated stability conditions the formulation was 
analyzed for various evaluation parameters; results were shown in Table 8.23 and 
Figures 8.39, 8.40 and 8.41.  
Table 8.14: Stability studies of best formulation (GF9) 
Stability 
chamber  
Time  Appearance  Hardness 
(kg/cm²)  
Friability(%)  Drug 
content (%)  
%drug 
release  
 
Initial White 6.30±0.10 0.631±0.06 98.56±1.12 98.2±0.55 
40±2°C with 1
st
 
month 
No change 6.25±0.32 0.627±0.09 98.39±0.55 97.8±0.23 
75±5°%RH 2
nd
 
month 
No change 6.23±0.09 0.622±0.05 97.94±0.20 97.3±0.02 
 
3
rd
 
month 
No change 6.18±0.06 0.614±0.10 97.63±0.08 96.9±0.30 
                        *All the values were expressed as mean± S.D., n=3. 
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Figure 8.30: Comparison for friability before and after stability studies of best      
                      formulation GF9. 
 
 
Figure 8.31: Comparison for hardness before and after stability studies of best      
                      formulation GF9. 
Sustained release matrix tablets of gliclazide                              Results and discussion 
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  106 
 
 
Figure 8.32: Comparison for drug content before and after stability studies of best      
                      formulation GF9. 
 
Figure 8.33 Comparisons for in vitro drug release profile of before and after stability  
 studies of best formulation GF9. 
 
From the above studies there was no significance differences was initiate 
between the evaluated data from initial and after stability studies and all the values 
were found to be accepting limits. The best formulation was showed           adequate 
physical stability at 40oC ± 2oC at 75% ± 5% relative humidity.  
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9. SUMMARY AND CONCLUSION 
             
               Oral route has been the commonly adopted and most convenient route for the 
drug delivery. Oral route of administration has been received more attention in the 
pharmaceutical field because of the more flexibility in the designing of dosage form 
than drug delivery design for other routes. The oral route of delivery is perhaps the 
least invasive method of delivering drugs, it’s a route that the patient understand and 
accepts, patient are able to administer the medicine to themselves. For the 
manufacturer, solid oral dosage form offer many advantages; are generally the most 
stable forms of drugs, are compact and their appearance can be modified to create 
brand identification. 
            Gliclazide was chosen as a drug having soluble in intestinal pH. Gliclazide 
plays a major role in treatment of Diabetic mellitus type2.  The drug half-life in 
plasma is 10.4 hours. It is bound to plasma proteins 85 to 95%. Gliclazide is rapidly 
absorbed with a bioavailability of over 97% following oral ingestion, hence it was 
considered as an good candidate for the design of oral sustained release dosage form.   
           In the present study, an attempt was made to formulate the oral sustained 
release matrix tablets of gliclazide to provide a dosage form for prolonged period of 
time, in order to improve efficacy, reduce the frequency of total dose and better 
patient compliance. Infrared spectroscopy and differential scanning calorimetric 
analysis confirmed the absence of any drug polymer interaction. 
              The sustained release matrix tablets were prepared by the direct compression 
method using different polymers like hydroxypropyl methylcellulose, and 
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ethylcellulose as release retardant polymers. The powders were evaluated for angle of 
repose, bulk density, compressibility index and hausner’s ratio. All the tests revealed 
that powders showed excellent flow properties. 
           The resulting monolithic tablets were evaluated for thickness, diameter, weight 
variation test, hardness, friability and drug content. All the tablet formulations showed 
acceptable pharmacotechnical properties and complied with pharmacopoeial 
standards. The in vitro release profiles from tablets of drug and different polymer ratio 
were applied on various kinetic models. In vitro release studies revealed that the 
release rate was decreased with increase in polymer proportion.  
            In the present studies, matrix formulation GF9 containing HPMC K100M and 
ethyl cellulose were probably showing maximum retardation of drug release and it 
shows anomalous diffusion mechanism, for these reasons, it was considered that the 
formulation GF9 as best formulation among all the nine formulations. Based on 
release exponent (n) values, it was concluded that mechanism of drug release was 
found to be diffusion coupled with erosion (anomalous transport mechanism).  
From the stability studies, there was no significance difference in hardness, 
friability,  drug content and in vitro release profile for the best formulation. 
  
 
 
 
 
FUTURE  
PROSPECTS
Sustained release matrix tablets of gliclazide               Future prospects 
Adhiparasakthi college of pharmacy, Melmaruvathur.  109 
 
10.  FUTURE PROSPECTS 
 
     In the present work, the sustained release matrix tablets of gliclazide were 
prepared by direct compression technique using synthetic polymers like 
hydroxypropyl methylcellulose,  and ethylcellulose as release retardant polymers. 
 In this work, only physiochemical characterization such as angle of repose, 
Carr’s index, hausner ratio, weight variation, hardness, thickness, friability, drug 
content and in vitro evaluation of matrix tablet of gliclazide was performed. Along 
with in vitro studies, in vivo studies of drug is most important. 
In future in vivo studies are required to set the in vitro - in vivo            
correlation (IVIVC) which is necessary for development of successful         
formulation and also long term stability studies are necessary. 
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